WO2000027627A1 - Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles - Google Patents

Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles Download PDF

Info

Publication number
WO2000027627A1
WO2000027627A1 PCT/US1999/026803 US9926803W WO0027627A1 WO 2000027627 A1 WO2000027627 A1 WO 2000027627A1 US 9926803 W US9926803 W US 9926803W WO 0027627 A1 WO0027627 A1 WO 0027627A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
arylalkyl
compound
resin
Prior art date
Application number
PCT/US1999/026803
Other languages
French (fr)
Inventor
Michael Robert Wiley
Salvatore Donato Lepore
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to AU18184/00A priority Critical patent/AU1818400A/en
Publication of WO2000027627A1 publication Critical patent/WO2000027627A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/021,2-Oxazines; Hydrogenated 1,2-oxazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to a solid support mediated method for the synthesis of polycyclic heterocycle compounds, as well as intermediate compounds, a library of polycyclic heterocycle compounds, a method for the synthesis of a library of diverse polycyclic heterocycles and an assay kit for the identification of compounds having biological or other activity.
  • VIM benzisoxazole scaffold
  • Suh et al. teach compounds having the benzisoxazole scaffold that are potent LTB receptor antagonists. (Suh, H.; Jeong, S.;Han, Y.N.; Lee, H.; Ryu, J. Bioorg. Med. Chem. Lett., 1997, 7, 389).
  • polycyclic heterocycles have been synthesized according to chemistry known in the art by several groups. Much of the synthesis has relied on conventional "solvent" based chemistry.
  • Solvent defined chemistry relies on the collision of discrete reactants within a solvent cage. The movement of reactants is controlled by kinetic and thermodynamic molecular fluid energetics. For example, Shutske et al. generated benzisoxazoles according to Scheme A, through the solvent defined NOT FURNISHED UPON FILING
  • the desired product is isolated from a refluxing 1 :1 ethanol:5% HCI solution of the corresponding aryl oxime.
  • Cyclorelease or cyclization and release are terms applied to a reaction that forms a cyclized system with simultaneous release of product from a solid support.
  • the phrase, cyclization and displacement of product from a solid support is used to mean the same reaction.
  • Combinatorial chemistry allows researchers to make collections, or libraries, of compounds by parallel synthesis of large numbers of derivatives of selected classes of organic compounds that can be screened for biological and other activities. By screening these compounds against key receptors or enzymes, useful structure-function data can be obtained, speeding the search for new therapeutic agents.
  • a solid support mediated method for the synthesis of polycyclic heterocycle compounds and the use of this solid support mediated method for the synthesis of a library of diverse polycyclic heterocycles is desirable.
  • One aspect of this invention relates to a solid support mediated method for the synthesis of polycyclic heterocycle compounds (V):
  • n is an integer > 0, preferably 0, 1 , 2, or 3 and most preferably 0 or 1.
  • polycyclic heterocycles of the general Formula (V) are synthesized according to a procedure comprising the steps of:
  • intermediate (IV) is optionally chemically derivatized where at least one of R 1 , R 2 , R 3 or R 4 is chemically altered to form a corresponding intermediate (IV):
  • a second aspect of the invention is an intermediate compound of formula IV or IV above. Because this intermediate may be chemically derivatized before cyclization and displacement to thereby provide further options for the groups R 1 , R 2 , R 3 and R 4 ; the intermediate is preferably stable to a wide range of chemical conditions.
  • a third aspect of the invention is directed to a library of polycyclic heterocycle compounds where this library contains a plurality of diverse compounds (V):
  • a fourth aspect of the invention is directed to a method for the synthesis of a library of diverse polycyclic heterocycles by the general method described above.
  • a fifth aspect of the invention is directed to an assay kit for the identification of compounds having biological or other activity, this kit comprising assay materials and well plate apparatus where each well in this apparatus contains a compound of the library described above.
  • solid support is intended to have a relatively broad meaning including, but not limited to, a resin, a polymer, a gel, glass beads, silica gel, a ceramic solid support or other solid composition.
  • solid support bound oxime means a solid support that at least has one oxime moiety chemically attached thereto.
  • this compound may be represented by the formula (IX):
  • g represents a solid support, such as defined above.
  • solid support bound member means a solid support that has at least one functional moiety chemically attached thereto.
  • this may be represented by the formula (III):
  • oxime resin means a solid support where the functional moiety is an oxime, and the solid support is a resin.
  • Kaiser resin means an oxime functionalized polystyrene resin, an example of that is defined by E.T.Kaiser in a 1980 publication (Degrado, W.F.;Kaiser. E.T.; J.Org. Chem., 1980, 45, 1295).
  • a preferred resin is an oxime functionalized polystyrene, such as an oxime-polystyrene resin derived from p-nitrobenzophenone polystyrene resin according to the following formula.
  • halo means a member selected from the group consisting of fluoro, chloro, bromo and iodo.
  • Alkyl is the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl group, and that groups may include one or more double or triple bonds.
  • a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone, and more preferably 20 or fewer and most preferred 10 or fewer.
  • preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 3-6 carbons in the ring structure.
  • Particularly preferred alkyl substituents include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, iso-butyl, tert-butyl, sec- butyl, cyclobutyl, pentyl, hexyl, cyclohexyl, etc.
  • "lower alkyl” as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure.
  • the aliphatic cyclic groups can be single or polycyclic containing between about 3 to 12 carbons per ring, but preferably between 3 and 9 carbons per ring.
  • Haloalkyl and “alkylhalo” both refer to mono- or poly- halogen radical substituted alkyl radicals, with the alkyl radicals having the analogous length and possible substitution as described above. Typically, these terms refer to groups of the formula X n -(CX'X") m -, where n and m are each independently an integer > 1 , and X, X' and X" are each independently hydrogen or halogen (so long as at least one of X, X and X" are halogen).
  • Hydroxyalkyl and “alkylhydroxide” and “alkyl alcohol” all refer to a mono or poly hydroxide radical substituted alkyl radical, with the alkyl radicals having the analogous length and possible substitution as described above.
  • Alkyloxyalkyl ether and “alkyloxyaryl ether” both refer to ether functional radicals of either the dialkyl radical or the alkyl, aryl radical configuration, with the alkyl radicals and the aryl radicals having the analogous length and possible substitution to the alkyl and aryl radicals defined herein.
  • Alkenyl and “alkynyl” refer to unsaturated aliphatic substituents analogous in length and possible substitution to the alkyl radicals described above, but that contain at least one double or triple bond, respectively.
  • Amino means an amino radical substituted with up to 2 alkyl radicals as defined above or with 1 alkyl radical and a hydrogen radical, or with two or more hydrogen radicals or with the substitution required to complete the nitrogen's valence requirements.
  • Aryl as used herein includes 5-10 membered aromatic monocyclic or fused polycyclic moieties that may include from zero to four heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, naphthyline, benzathiazoline, benzothiapene, benzofurans, indole, quinoline, etc.
  • the aryl group can be substituted at one or more positions with halo, alkyl, alkoxy, alkoxy carbonyl, haloalkyl, cyano, amino sulfonyl, aryl, sulfonyl, aminocarbonyl, carboxy, acylamino, alkyl sulfonyl, amino and substituted or unsubstituted substituents.
  • heteroaryl is a mono-, bi- or tricyclic, -N-, -O- or -S- heteroaryl substituent, such as benzofuran, benzothiophene, furan, imidazole, indole, isothiazole, oxazole, piperazine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinoline, thiazole and thiophene.
  • a "library” means a large number of chemical derivatives used in screening for biological activity or other activity.
  • a library will have greater than 20 members, preferably the library will have at least 50 members, more preferably the library will have at least 96 members and most preferably the library will have at least 1000 members.
  • chemically derivatized means the chemical manipulation such as addition to, oxidation of, substitution for, reduction of, or cyclization of the selected R group or R groups of the intermediate. Chemical derivatization also means the manipulation of two or more groups of the intermediate such that additional aryl or alkyl rings are formed and that rings may be fused or unfused to the intermediate ring, and that new ring may be substituted with further chemically derivatizable substituents.
  • pharmaceutically acceptable salt and “salts thereof means organic or inorganic salts of the pharmaceutically important molecule.
  • a pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion.
  • the counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound.
  • a pharmaceutically important organic molecule may have more than one charged atom in its structure. Situations where multiple charged atoms are part of the molecule may have multiple counterions.
  • the molecule of a pharmaceutically acceptable salt may contain one or more than one charged atoms and may also contain, one or more than one counterion.
  • the desired charge distribution is determined according to methods of drug administration.
  • Examples of pharmaceutically acceptable salts are well known in the art but, without limiting the scope of the present invention, exemplary presentations can be found in the Physician's Desk Reference, The Merck Index, The Pharmacopoeia and Goodman & Gilman's The Pharmacological Basis of Therapeutics.
  • TFA means trifluoro acetic acid
  • HCI means hydrochloric acid
  • THF means tetrahydrofuran
  • DMF means dimethylformamide
  • DIPEA diisopropylethyl amine
  • TMS means a trimethyl silyl radical
  • TBS means a f-butyldimethyl silyl radical.
  • leaving group means halo, oxo, thioxo radicals and activated alcohols such as a p-toluene sulfonyl activated alcohols and other groups that are susceptible to displacement and replacement by a nucleophile under selected conditions of temperature, solvent and time.
  • scaffold means a common chemical structure found within a library of organic compounds. Similarly, within a combinatorial chemical library the scaffold forms the basis for a diverse series of chemical derivatization, additions and subtractions. Importantly, regardless of the extent of the chemical derivatization performed on the scaffold, the product is within the scope of the combinatorial library.
  • a general method for making polycyclic heterocyles according to the first aspect of the invention involves the following method.
  • each of R 1 , R 2 , R 3 and R 4 is a stable moiety independently selected from the group consisting of halo, haloalkyl, cyano, nitro, R a -Q-, R a -Q-alkyl, R a -Q- alkenyl, R a -Q-alkynyl, R a -Q-arylalkyl and R a -Q-aryl;
  • R a is hydrogen, alkyl, aryl or arylalkyl;
  • R b is hydrogen, alkyl, aryl or arylalkyl, where R a and R may together with the nitrogen to that they are attached form a ring, R 5 is selected from the group consisting of halo, nitro, and haloalkyl.
  • each of R 1 , R 2 , R 3 and R 4 may be substituted one to three times with a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, halo, hydroxy, alkoxy, alkylthio, sulfonyl, aryl, heteroaryl and where the substituents of the moieties substituted can themselves be substituted with one to three further substituents, if desired.
  • a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, halo, hydroxy, alkoxy, alkylthio, sulfonyl, aryl, heteroaryl and where the substituents of the moieties substituted can themselves be substituted with one to three further substituents, if desired.
  • R , R 2 , R 3 or R 4 is an haloalkyl, more particularly either R 1 , R 3 or R 4 is a CF 3 radical and most particularly R 3 is a
  • R 1 , R 2 , R 3 or R 4 is an hydroxyalkyl, more particularly one of R 1 , R 2 , R 3 or R 4 is methoxy and most particularly R 3 is a methoxy radical.
  • R 1 , R 2 , R 3 or R 4 is halo, cyano or nitro.
  • R 1 , R 2 , R 3 or R 4 is bromo, and most particularly R 3 is bromo.
  • R 3 is most particularly a cyano radical.
  • R 3 is most particularly a nitro radical.
  • R 5 is selected from fluoro, chloro or nitro. If a 5,6 polycycle is desired, then R 5 is a halo. Also, R 5 is between C- ⁇ to C ⁇ 2 haloalkyl, particularly R 5 is between Ci to C 6 haloalkyl and more particularly R 5 is a halomethyl and most particularly R 5 is bromomethyl.
  • R 6 of formula (I) is selected from the group consisting of cyano and a radical of formula (II) where L is selected from the group consisting of -0-, -S- and -NH-.
  • L is preferably -O- or -S- and most preferably -O-.
  • R 7 of formula (II) is selected from the group consisting of alkyl, aryl, arylalkyl, alkyloxyalkyl, aryloxyalkyl, alkylamino, dialkylamino, arylamino, alkoxy carbonyl, amino, alkoxy, hydroxy and heteroaryl.
  • R 6 is a radical of formula (II)
  • R 7 is preferably aryl and most preferably R 7 is phenyl.
  • R 5 is halomethyl and R 6 is cyano.
  • R 5 is halo
  • R 6 is formula (II)
  • L is oxygen and R 7 is a phenyl radical.
  • R 5 is halo and R 6 is cyano.
  • the compound (I) is reacted with the solid support bound member (III) under suitable conditions for a desired period of time and at a desired temperature such that the compound (I) is reacted with the compound (III).
  • g is a solid support selected from the group consisting of a resin, a polymer, a gel, glass beads, silica gel, a ceramic solid support or other solid composition. More preferably the solid support is a resin and most preferably the solid support is a polystyrene resin.
  • h is selected from the group consisting of alkyl and aryl.
  • h is aryl, more preferably h is a substituted aryl and most preferably h is p-nitrophenyl.
  • R 13 is selected from the group consisting of -
  • R 13 is -O-.
  • Suitable conditions for this reaction include having a suitable solvent mixture, a suitable temperature and reacting for a suitable period of time.
  • a suitable solvent mixture is preferably of basic pH.
  • the base is an alkoxide, more preferably the base is an alkoxide of fewer than 5 carbons and most preferably the base is K + OBu*.
  • a suitable solvent is either protic or aprotic, preferably the solvent is aprotic and even more preferably the solvent is aprotic and anhydrous and most preferably the solvent is THF.
  • the reaction temperature is preferably between about 0° C and 85° C but more preferably between about 30° C and about 70° C and most preferably at about 55° C.
  • the reaction time is preferably between about 1 minute and 2 days, more preferably between about 1 hour and 1 day and most preferably between about 8 hours and 14 hours.
  • the compounds (I) and (III) react forming an intermediate (IV) where n > 0, and g, h, R 1 , R 2 , R 3 , R 4 , R 6 and R 13 are as defined above.
  • This intermediate (IV) is optionally chemically derivatized prior to the cyclization and displacement procedure.to form a corresponding intermediate (IV):
  • R 1 , R 2 , R 3 and R 4 substituents are each independently the same as substituents R 1 , R 2 , R 3 and R 4 respectively if not derivatized or are each independently the chemically derivatized substituents respectively.
  • Examples of chemical derivatization reactions include, but are not limited to, the following general derivatizations procedures.
  • R' , R , R° and R 4 substituents are each independently the same as substituents R 1 , R 2 , R 3 and R 4 respectively if not derivatized or are each independently the chemically derivatized substituents respectively.
  • each of R 1 , R 2 , R 3 and R 4 may be correspondingly the same as R 1 , R 2 , R 3 and R 4 or may represent the result of the optional chemical derivatization of the corresponding substituent, prior to cyclization and displacement.
  • chemical derivatization includes other ring formation or ring closure reactions such as where any two of R 1 , R 2 , R 3 and R 4 together form an aryl or an alkyl ring of between about 5 and 14 atoms.
  • R 7 is amino, hydroxy or the same as R 7 above.
  • the temperature for the cyclization and displacement procedure may be between about 0° and 85° C but is preferably between about 30° and 70° and is most preferably at about 55° C.
  • the solvents suitable for the cyclization and displacement procedure include protic and aprotic solvent mixtures, aqueous and anhydrous solvent mixtures.
  • a preferred solvent is TFA
  • a more preferred solvent mixture is TFA:H O
  • a most preferred solvent mixture is TFA:5 N HCI/H 2 0.
  • the ratio of this TFA:5 N HCI/H 2 O mixture may vary between about 1 :1 to about 99:1 TFA:5 N HCI/H 2 0, but preferably is between about 80:1 to 1 :1 TFA:5 N HCI/H 2 O, and is most preferably at about 4:1 TFA:5 N HCI/H 2 O.
  • the time for the cyclization and displacement reaction may vary, but generally is between about 1 minute and 4 days but preferably between about 1 hour and 20 hours.
  • a second aspect of the invention is directed to a solid support bound intermediate (IV) above.
  • the intermediate (IV) can be derivatized before the cyclization and displacement procedure to thereby provide further options for the groups R 1 , R 2 , R 3 and R 4 in the final product.
  • the preferred, yet optional, derivatizations of the intermediate compound (IV), and preferred conditions whereby optional derivatizations occur are as described above.
  • a third aspect of the invention is directed to a library of polycyclic heterocycle compounds where the library contains a plurality of diverse compounds (V):
  • each of R 1 , R 2 , R 3 and R 4 is a stable moiety independently selected from the group consisting of halo, haloalkyl, cyano, nitro, R a -Q-, R a -Q-alkyl, R a -Q- alkenyl, R a -Q-alkynyl, R a -Q-arylalkyl and R a -Q-aryl;
  • R a is hydrogen, alkyl, aryl or arylalkyl
  • R b is hydrogen, alkyl, aryl or arylalkyl, where R a and R b may together with the nitrogen to that they are attached form a ring, and n > 0; and R 7 is selected from the group consisting of alkyl, aryl, arylalkyl, alkyloxyalkyl, aryloxyalkyl, alkylamino, dialkylamino, arylamino, alkoxy carbonyl, amino, alkoxy, hydroxy and heteroaryl; and
  • R 13 is selected from the group consisting of -NH-, -O- and -S-.
  • Preferred substituents for R 1 , R 2 , R 3 , R 4 , R 7 , and values for n are as described above, in the included examples and the appended claims.
  • a fourth aspect according to the present invention preferably produces a library of compounds where the compounds comprise a diverse chemical library according to the general methods discussed above. All of the compounds in such a library have a common scaffold, e.g., compound (V).
  • R 1' , R 2 , R 3 , R 4 , R 7 , and R 13 substituents are selected to allow the creation of a chemically diverse library that, as one goal, maximizes the exploration of molecular spatial properties. Such maximization increases the likelihood of creating compounds that will be biologically active against selected targets.
  • a fifth aspect of the invention is directed to an assay kit for the identification of biologically active compounds, the kit comprising assay materials and a well plate apparatus where each well in the apparatus contains a compound of the library described above.
  • the fourth and fifth aspects of the solid support mediated method of the invention may be carried out by way of parallel synthesis in any reaction vessel capable of holding the liquid reaction medium and having, preferably, inlet and outlet means.
  • the solid support mediated method of the invention is preferably carried out in containers adaptable to parallel array syntheses.
  • parallel array synthesis individual reaction products are prepared in each of multiple reaction zones.
  • the reaction zones are physically separated from one another in a reaction vessel.
  • Compounds can be added to the reaction vessel by multiple delivery apparatus, automated or robotic apparatus, any of that may be either manually or computer controlled.
  • a preferred parallel synthesis embodiment of the present invention is a diverse polycyclic heterocycle compound library in the form of a plurality of wellplates, each wellplate having wells containing a separate reaction product (library compound).
  • libraries compound a separate reaction product
  • their wellplate number and "x" column and "y" wellplate row coordinates conveniently identify the library compounds.
  • the process of making the library of polycyclic heterocycle compounds may be conveniently carried out in a conventional wellplate apparatus. It is particularly advantageous to carry out the method of the invention in a standard wellplate apparatus such as a plastic 96 well microtiter plate.
  • the wellplate apparatus is in the form of a rigid or semi-rigid plate, the plate having a common surface containing openings of a plurality of reservoirs arranged in rows and columns.
  • a standard form of wellplate apparatus is a rectangular plastic plate having 8 rows and 12 columns (total 96) of liquid retaining depressions, or reservoirs, on its surface.
  • a wellplate apparatus may optionally have other elements of structure such as a top or cover (e.g., plastic or foil), a bottom in a form such as a plate or reservoir, clamping means to secure the wellplate and prevent loss of its contained compounds.
  • the polycyclic heterocycle library of compounds formed using the solid support mediated method aspects of the invention can be used to screen compounds for biological or other activity.
  • Myriad biological assays are known in the art and can be used to screen the polycyclic heterocycle library of compounds.
  • the libraries of diverse polycyclic heterocycle according to the solid support mediated method of the present invention may be screened for biological activity.
  • the library to be screened is exposed to a biological substance, usually a protein such as a receptor, enzyme, membrane binding protein or antibody, and the presence or absence of an interaction between the heterocycle derivative and the biological substance is determined.
  • a biological substance usually a protein such as a receptor, enzyme, membrane binding protein or antibody
  • this will comprise determining whether the biological substance is bound to one or more of the members of the library.
  • binding may be determined by attaching a label to the biological substance.
  • Commonly used labels include fluorescent labels. Other methods of labeling may be used, such as radioactive labels.
  • the degree of binding affinity may be determined by quantitating the amount or intensity of the bound label.
  • various biologically active compounds may be selected by identifying that compounds bind the particular biological substance most effectively.
  • additional assays include but are not limited to in vitro assays such as enzymatic inhibition, receptor - ligand binding, protein - protein interaction, andprotein - DNA interaction; cell based, functional assays such as transcriptional regulation, signal transduction / second messenger, and viral infectivity; add, incubate & read assays such as scintillation proximity assays (SPA), fluorescence polarization assay, fluorescence correlation spectroscopy, colorimetric biosensors, cellular reporter assays using reporter genes such as luciferase, green fluorescent protein, ⁇ -lactamase, and the like; and electrical cell impedance sensor assays.
  • in vitro assays such as enzymatic inhibition, receptor - ligand binding, protein - protein interaction, andprotein - DNA interaction
  • cell based, functional assays such as transcriptional regulation, signal transduction / second messenger, and
  • Table A lists representative moieties that are substituted for R on the designated position of the starting compound. Because the moieties are representative of a general class of organic substituents, it is meant that other organic substituents are chemically equivalent to those given in Table A and are within the scope of the invention and appended claims.
  • the CF 3 radical replaces R 3
  • the placement of the same group in position 4, 5 or 6 is an equivalent analogue.
  • the CF 3 placed at each of positions 3, 4, 5, 6 or any combination thereof is within the scope of this invention and appended claims.
  • the CF 3 group is, optionally, meant to represent an electron withdrawing group and can therefor be replaced by other electron withdrawing groups such as polyhalo-alkyl and be within the scope of this invention.
  • the solid support bound oxime is reacted with the fluorobenzonitrile of Example 1 under suitable conditions to form the solid support bound intermediate.
  • the solid support bound intermediate is optionally isolated and finally subjected to the cyclization and displacement procedure.
  • the nitrogen and oxygen of the solid support bound oxime are involved in the cyclization and displacement reaction and become part of the polycyclic heterocycle.
  • the solid support mediated method includes analogues involving substituents at each available position of the aromatic scaffold, such as a tri or tetra substituted phenyl.
  • analogues involving substituents at each available position of the aromatic scaffold, such as a tri or tetra substituted phenyl.
  • R is methoxy
  • a Ci to C ⁇ 2 alkoxy is considered an equivalent analogue.
  • the substituent group is Br
  • another halo substituent such as -F or -CI is an equivalent analogue.
  • the solid support mediated method according to the present invention further allows for the optional chemical derivatization of none, any, or all of R 1 , R 2 , R 3 R 4 substituents of the solid support bound intermediate as provided above.
  • the solid support bound intermediate is preferably stable to a broad range of reaction conditions.
  • Table B lists substituted aromatic compounds (I), which are reacted with the solid support bound member, thereby forming the solid support bound intermediate (IV), are chemically derivatized with final cyclization and displacement of the corresponding polycyclic heterocycle.
  • the compounds of Table B are synthesized according to the solid support mediated method of the present invention. This list is intended to demonstrate the diversity of compounds that are synthesized according to this invention and is not intended to limit the scope in any way.
  • the resin bound intermediates of the present invention were surprisingly stable to conditions suitable for optional derivatizations such as, BOC removal/acylation, TBS removal and Mitsunobu coupling, Suzuki coupling, Sonogashira coupling, Hoerner-Emmons olefination, and ester hydrolysis/amidation reaction conditions. These and other reactions discussed were performed according to the following detailed chemical procedure.
  • the loaded resin was removed from the oven and allowed to cool for 1 h and rinsed with 2 x 5 mL of CH 2 CI 2 , 2 x 5 mL of 5% TFA/CH 2 CI 2 , 2 x 5 mL of isopropanol and 4 x 5 mL of MeOH. This was dried in a 35° C vacuum oven for 12 h. Next, 4 mL of TFA and 1mL of aqueous 5 N HCI were then added to the resin followed by turning for 2 h in a 55° C oven. The TFA/H 2 O was collected and the resin was rinsed with 2 x 5 mL of CH 2 CI 2 .
  • the loaded resin was removed from the oven and allowed to cool for 1 h and rinsed with 2 x 5 mL of CH 2 CI 2 , 2 x 5 mL of 5% TFA/CH 2 CI 2 , 2 x 5 mL of isopropanol 4 x 5 mL of MeOH. This was dried in a 35° C vacuum oven for 12 h. Next, 4 mL of TFA and 1mL of aqueous 5 N HCI were then added to the resin followed by turning for 8 h in a 55° C oven. The TFA/H 2 O was collected and the resin was rinsed with 2 x 5 mL of CH 2 CI 2 .
  • This reaction vessel was placed in a 55 °C oven fitted with a rotating device for 12 h. This was removed from the oven and allowed to cool for 1 h and rinsed with 2 x 5 mL of CH 2 CI 2, 2 x 5 mL of isopropanol, and 4 x 5 mL of isopropanol, and 4 x 5 mL of MeOH. This was dried in a 35 °C vacuum oven for 12 h. BOC-deprotection was achieved using 25% TFA/CH 2 CI 2 (7 mL) followed by shaking for 2 h.
  • Resin was again rinsed with 2 x 5 mL of CH 2 CI 2 , 2 x 5 mL of isopropanol, and 4 x 5 mL of MeOH.
  • the resin was suspended in DMF followed by addition of acetic anhydride and diisopropylethylamine. This was allowed to shake for 3h and was rinsed with 2 x 5 mL of CH 2 CI 2 , 2 x 5 mL of isopropanol, and 4 x 5 mL of MeOH. 4 mL of TFA and 1 mL of aqueous 5 N HCI were then added to the resin followed by turning for 2 h in a 55° C oven.
  • the resin was rinsed with 2 x 5 mL of CH 2 CI 2 , 2 x 5 mL H 2 O, 4 x 5 mL of MeOH. This was dried in a 35° C vacuum oven for 12 h.
  • the resin was suspended in 8 mL of 1:1 THF/CH 2 CI 2 followed by addition of triphenylphosphine (700mg, 5 equiv.) and 4-chlorophenol (690 mg, 10 equiv.). This was shaken by hand followed by the slow addition of diisopropyl azodicarboxylate (0.53mL 5 equiv).
  • Method A 4: 1 TFA/5N HCI, 55 °C.
  • Method B 99: 1 TFA/H 2 0, 55 °C.
  • Method C 25% THF/CH 2 C1 2 , room temp.
  • Method D TFA, 55 °C.
  • Method E AcOH/THF/H 2 0, 55 °C.
  • Method F TsOH/THF/H 2 0, 55 °C. isolated yield after chromatography and based on loading. Crude purity based on HPLC analysis.
  • Acid 6 was then coupled to 4-chlorobenzylamine to give the on-resin amide. Both the resin weight increase and chlorine analysis of the intermediate suggested that the coupling reaction went essentially to completion within 12 h. The resin was then treated with the standard cyclorelease conditions to give the desired amide 7 in a 3 step yield of 81% (93% crude purity).
  • the reaction vessel was rotated at 55 °C in a Robbins oven for 12 h to give resin 5 followed by cooling for 1 h.
  • the resin was then rinsed with 2 x 5 mL of CH 2 CI 2 , 2 x 5 mL of MeOH, 2 x 5 mL of H 2 0, and 4 * 5 mL of MeOH.
  • the resin was then suspended in THF (7 mL) followed by the addition of LiOH (39 mg, 1.61 mmol) dissolved in MeOH/H 2 O (1 :1 , 2 mL) and rotated at room temp, for 12 h.
  • the resin was then rinsed with 2 * 5 mL of CH 2 CI 2 , 2 x 5 mL of MeOH, 2 x 5 mL of H 2 O, 2 x 5 mL of MeOH, and 2 x 5 mL of DMF.
  • the resin was then suspended in DMF (7 mL) and to this was added p- chlorobenzylamine (261 ⁇ L, 2.14 mmol), 1-hydroxybenzotriazole hydrate (HOBt) (289 mg, 2.14 mmol), benzotriazole-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (947 mg, 2.14 mmol), and diisopropylethylamine (DIPEA) (467 ⁇ L, 2.68 mmol). The reaction was allowed to proceed for 12 h at room temp.
  • the resin was then rinsed 2 5 mL of CH 2 CI 2 , 2 5 mL of MeOH, 2 x 5 mL of H 2 0, and 4 5 mL of MeOH.
  • TFA (4 mL) and 5 N HCI aq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven. The TFA/HCI aq was collected and the resin was rinsed with 2 x 5 mL of CH2CI2.
  • Phenolic Mitsunobu reaction On-resin carbon-oxygen bond formation via the Mitsunobu reaction has been identified as an important tool in combinatorial chemistry (Kaldor, S.W.; Siegel, M.G. Comb. Chem. Mol. Diversity Drug Discovery 1998, 307-335. Editors: Gordon, Eric M.; Kerwin, James F., Jr. Publisher: Wiley- Liss, New York, N. Y).
  • Application of this reaction to an aryl oxime-linked substrate is shown in Scheme 3.
  • Resin 8 was prepared by reacting the potassium anion of the Kaiser resin 1 with 2-fluoro-4-( -butyl-dimethylsilyloxymethyl)-benzonitrile.
  • the TBS- protecting group was removed using TBAF in THF.
  • the on-resin alcohol was then treated with p-chlorophenol, triphenylphosphine and diisopropylazodicarboxylate (DIAD) in THF.
  • DIAD diisopropylazodicarboxylate
  • the best results were observed for reactions times of 3 h. Longer reaction times generally led to decreased purity in the crude cyclization product. Cyclitive removal using the standard conditions then gave aryl ether 9 in a 77% yield (3 steps) and 83% crude purity.
  • the resin was then suspended in THF (6 mL) followed by the addition of TBAF (562 ⁇ L, 1 M in THF, 0.562 mmol) and rotated at room temperature for 12 h.
  • the resin was then rinsed with 2 5 mL of CH 2 CI 2 , 2 x 5 mL of MeOH, 2 x 5 mL of H 2 O, 2 5 mL of MeOH, and 2 5 mL of CH 2 CI 2 .
  • the resin was then suspended in CH 2 CI 2 (7 mL) and to this was added p-chlorophenol (690 mg, 5.35 mmol), triphenylphosphine (700 mg, 2.68 mmol), and diisopropyl-azodicarboxylate (DIAD) (530 ⁇ L, 2.68 mmol). The reaction was allowed to proceed for 1 h at room temp. The resin was then rinsed 2 5 mL of CH 2 CI 2 , 2 5 mL of MeOH, 2 x 5 mL of H 2 O, and 4 5 mL of MeOH. The resin was dried in a 35 °C vacuum oven for 12 h.
  • the resin loading reaction may be quite selective for the 2-position, giving primarily 12, and then subsequently 14a upon cyclorelease.
  • mixtures of the two isomeric aryloxime adducts could be formed with the hydrolysis of intermediate 12 occurring much more rapidly than 13.
  • Scheme 5 depicts a solution phase model study for the loading reaction of 2,4- difluorobenzonitrile.
  • the potassium salt of acetone oxime was treated with 2,4-difluorobenzonitrile and showed only a slight preference for the addition to the 2-position (1.4:1).
  • Scheme 6 illustrates a comparison of the relative rates of hydrolysis for analogous 2- vs 4-substituted aryloximes. Since the isolation of pure 12 and pure 13 was not practical, model resins 3a and 15 were prepared from 2-fluorobenzonitrile and 4-fluorobenzonitrile respectively. As described previously, when resin 3a was treated with the standard cyclitive removal conditions, complete conversion to 3- aminobenzisoxazole was observed after 2h.
  • IR analysis of the resin shows a nitrile stretching peak at 2230.3 cm "1 .
  • TFA (4 mL) and 5 N HCI aq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven.
  • the TFA/HCI aq was collected and the resin was rinsed with 2 x 5 mL of CH 2 CI 2 .
  • An IR analysis of the resin after the cyclorelease reaction shows a diminished nitrile stretching peak.
  • a - D all use 4.0 eq of boronic acid and 5% Pd(PPh 3 ) 4 , and 36 h.
  • A 2.5 eq 2 M Na ⁇ O-,, DME, reflux;
  • B 1.0 eq 2 M Na 2 C0 3 , THF, 55 °C;
  • C 1.3 eq 2 M Na 2 C0 3 , THE, 55 °C;
  • D 1.5 eq 2 M Na 2 C0 3 , THF, 55 °C isolated yield after chromatography and based on loading. Crude purity based on HPLC analysis. Major impurity in all cases is 6-bromo-3-aminobenzisoxazole.
  • the vessel was then rotated for 36 h in a 55 °C oven followed by rinsing with 2 x 5 mL of CH 2 CI 2 , 2 x 5 mL of MeOH, 2 5 mL of H 2 0, and 4 x 5 mL of MeOH.
  • the resin was dried in a 35 °C vacuum oven for 3 h.
  • TFA (4 mL) and 5 N HCI aq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven.
  • the TFA/HCI aq was collected and the resin was rinsed with 2 x 5 mL of CH 2 CI 2 .
  • aldehyde resin 18 (Scheme 9) from the Suzuki reaction with 3b (Table 5, entry 4) provided an opportunity to evaluate the compatibility of the aryloxime linker with the Horner-Emmons olefination.
  • treatment of 18 with the anion of trimethylphosphonoacetate in THF preformed with n-BuLi at 0

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

In its first aspect, the invention is directed to a solid support mediated method for the synthesis of diverse polycyclic heterocycles according to general formula (V). A second aspect of the invention is directed to a solid support bound intermediate compound that optionally can be derivatized before a cyclization and displacement procedure provides a product. The intermediate is preferably stable to a wide range of chemical conditions thus allowing, if desired, for the chemical derivatization of the intermediate. A third aspect of the invention is directed to a library of polycyclic heterocycle compounds where said library contains a plurality of diverse library compounds of general formula (V). A fourth aspect of the invention is directed to a method for the synthesis of a library of diverse polycyclic heterocycles by the general method described. A fifth aspect of the invention is directed to an assay kit for the identification of lead compounds of the library described therein.

Description

ARYLOXIME LINKERS IN THE SOLID-PHASE SYNTHESIS OF 3- A INOBENZISOXAZOLES
BACKGROUND OF THE INVENTION
The present invention relates to a solid support mediated method for the synthesis of polycyclic heterocycle compounds, as well as intermediate compounds, a library of polycyclic heterocycle compounds, a method for the synthesis of a library of diverse polycyclic heterocycles and an assay kit for the identification of compounds having biological or other activity.
Compounds having the benzisoxazole scaffold (VIM) have been shown to have biological activity.
Figure imgf000003_0001
VIII
For example, Suh et al. teach compounds having the benzisoxazole scaffold that are potent LTB receptor antagonists. (Suh, H.; Jeong, S.;Han, Y.N.; Lee, H.; Ryu, J. Bioorg. Med. Chem. Lett., 1997, 7, 389). Thus, since the potential for using polycyclic heterocycles as therapeutic drugs is known, an efficient preparation that facilitates the synthesis of single polycyclic heterocycle compounds and the generation of a diverse library of polycyclic heterocycle compounds would be useful. Polycyclic heterocycles have been synthesized according to chemistry known in the art by several groups. Much of the synthesis has relied on conventional "solvent" based chemistry. Solvent defined chemistry relies on the collision of discrete reactants within a solvent cage. The movement of reactants is controlled by kinetic and thermodynamic molecular fluid energetics. For example, Shutske et al. generated benzisoxazoles according to Scheme A, through the solvent defined NOT FURNISHED UPON FILING
NO PRESENTADO(A) EN EL MOMENTO DE LA PRESENTACION
NON SOUMIS(E) AU MOMENT DU DEPOT
cyclization of cyano arylacetone oxime (Shutske, G.M.; Kapples, K.J.;J Hetrocyclic CA?em,1989, 26, 1293).
Figure imgf000005_0001
Scheme A
The desired product is isolated from a refluxing 1 :1 ethanol:5% HCI solution of the corresponding aryl oxime.
An alternative method for the generation of the benzisoxazole ring system involves a cyclorelease reaction. Cyclorelease or cyclization and release are terms applied to a reaction that forms a cyclized system with simultaneous release of product from a solid support. Alternatively, the phrase, cyclization and displacement of product from a solid support, is used to mean the same reaction.
Combinatorial chemistry allows researchers to make collections, or libraries, of compounds by parallel synthesis of large numbers of derivatives of selected classes of organic compounds that can be screened for biological and other activities. By screening these compounds against key receptors or enzymes, useful structure-function data can be obtained, speeding the search for new therapeutic agents. A solid support mediated method for the synthesis of polycyclic heterocycle compounds and the use of this solid support mediated method for the synthesis of a library of diverse polycyclic heterocycles is desirable.
SUMMARY OF THE INVENTION
One aspect of this invention relates to a solid support mediated method for the synthesis of polycyclic heterocycle compounds (V):
Figure imgf000006_0001
V
where n is an integer > 0, preferably 0, 1 , 2, or 3 and most preferably 0 or 1.
In the first aspect of the invention, polycyclic heterocycles of the general Formula (V) are synthesized according to a procedure comprising the steps of:
(a) reacting a compound (I):
Figure imgf000006_0002
with a solid support bound member (III):
Figure imgf000006_0003
thereby yielding an intermediate (IV):
Figure imgf000007_0001
IV
(b) intermediate (IV) is optionally chemically derivatized where at least one of R1, R2, R3 or R4 is chemically altered to form a corresponding intermediate (IV):
Figure imgf000007_0002
IV
(c) causing a cyclization reaction whereby a compound (V) is displaced from the solid support.
Figure imgf000007_0003
V
A second aspect of the invention is an intermediate compound of formula IV or IV above. Because this intermediate may be chemically derivatized before cyclization and displacement to thereby provide further options for the groups R1, R2, R3 and R4; the intermediate is preferably stable to a wide range of chemical conditions.
A third aspect of the invention is directed to a library of polycyclic heterocycle compounds where this library contains a plurality of diverse compounds (V):
Figure imgf000008_0001
V A fourth aspect of the invention is directed to a method for the synthesis of a library of diverse polycyclic heterocycles by the general method described above. A fifth aspect of the invention is directed to an assay kit for the identification of compounds having biological or other activity, this kit comprising assay materials and well plate apparatus where each well in this apparatus contains a compound of the library described above.
DETAILED DESCRIPTION Definition of terms
As used herein and in the appended claims the term "solid support" is intended to have a relatively broad meaning including, but not limited to, a resin, a polymer, a gel, glass beads, silica gel, a ceramic solid support or other solid composition.
As used herein and in the appended claims the term "solid support bound oxime" means a solid support that at least has one oxime moiety chemically attached thereto. For example, one embodiment of this compound may be represented by the formula (IX):
Figure imgf000009_0001
IX
In formula (IX), g represents a solid support, such as defined above.
As used herein and in the appended claims the term "solid support bound member" means a solid support that has at least one functional moiety chemically attached thereto. For example, this may be represented by the formula (III):
Figure imgf000009_0002
As used herein and in the appended claims the term "oxime resin" means a solid support where the functional moiety is an oxime, and the solid support is a resin.
As used herein and in the appended claims the term "Kaiser resin" means an oxime functionalized polystyrene resin, an example of that is defined by E.T.Kaiser in a 1980 publication (Degrado, W.F.;Kaiser. E.T.; J.Org. Chem., 1980, 45, 1295). A preferred resin is an oxime functionalized polystyrene, such as an oxime-polystyrene resin derived from p-nitrobenzophenone polystyrene resin according to the following formula.
Figure imgf000009_0003
As used herein and in the appended claims, "halo" means a member selected from the group consisting of fluoro, chloro, bromo and iodo. "Alkyl" is the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl group, and that groups may include one or more double or triple bonds. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone, and more preferably 20 or fewer and most preferred 10 or fewer. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 3-6 carbons in the ring structure. Particularly preferred alkyl substituents include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, iso-butyl, tert-butyl, sec- butyl, cyclobutyl, pentyl, hexyl, cyclohexyl, etc. Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure. The aliphatic cyclic groups can be single or polycyclic containing between about 3 to 12 carbons per ring, but preferably between 3 and 9 carbons per ring.
"Haloalkyl" and "alkylhalo" both refer to mono- or poly- halogen radical substituted alkyl radicals, with the alkyl radicals having the analogous length and possible substitution as described above. Typically, these terms refer to groups of the formula Xn-(CX'X")m-, where n and m are each independently an integer > 1 , and X, X' and X" are each independently hydrogen or halogen (so long as at least one of X, X and X" are halogen).
"Hydroxyalkyl" and "alkylhydroxide" and "alkyl alcohol" all refer to a mono or poly hydroxide radical substituted alkyl radical, with the alkyl radicals having the analogous length and possible substitution as described above. "Alkyloxyalkyl ether" and "alkyloxyaryl ether" both refer to ether functional radicals of either the dialkyl radical or the alkyl, aryl radical configuration, with the alkyl radicals and the aryl radicals having the analogous length and possible substitution to the alkyl and aryl radicals defined herein. "Alkenyl" and "alkynyl" refer to unsaturated aliphatic substituents analogous in length and possible substitution to the alkyl radicals described above, but that contain at least one double or triple bond, respectively.
"Amino" means an amino radical substituted with up to 2 alkyl radicals as defined above or with 1 alkyl radical and a hydrogen radical, or with two or more hydrogen radicals or with the substitution required to complete the nitrogen's valence requirements.
"Aryl" as used herein includes 5-10 membered aromatic monocyclic or fused polycyclic moieties that may include from zero to four heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, naphthyline, benzathiazoline, benzothiapene, benzofurans, indole, quinoline, etc. The aryl group can be substituted at one or more positions with halo, alkyl, alkoxy, alkoxy carbonyl, haloalkyl, cyano, amino sulfonyl, aryl, sulfonyl, aminocarbonyl, carboxy, acylamino, alkyl sulfonyl, amino and substituted or unsubstituted substituents.
As used herein and in the appended claims, "heteroaryl" is a mono-, bi- or tricyclic, -N-, -O- or -S- heteroaryl substituent, such as benzofuran, benzothiophene, furan, imidazole, indole, isothiazole, oxazole, piperazine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinoline, thiazole and thiophene.
As used herein and in the appended claims a "library" means a large number of chemical derivatives used in screening for biological activity or other activity. In general a library will have greater than 20 members, preferably the library will have at least 50 members, more preferably the library will have at least 96 members and most preferably the library will have at least 1000 members.
As used herein and in the appended claims "chemically derivatized" means the chemical manipulation such as addition to, oxidation of, substitution for, reduction of, or cyclization of the selected R group or R groups of the intermediate. Chemical derivatization also means the manipulation of two or more groups of the intermediate such that additional aryl or alkyl rings are formed and that rings may be fused or unfused to the intermediate ring, and that new ring may be substituted with further chemically derivatizable substituents.
As used herein and in the appended claims "pharmaceutically acceptable salt" and "salts thereof means organic or inorganic salts of the pharmaceutically important molecule. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically important organic molecule may have more than one charged atom in its structure. Situations where multiple charged atoms are part of the molecule may have multiple counterions. Hence, the molecule of a pharmaceutically acceptable salt may contain one or more than one charged atoms and may also contain, one or more than one counterion. The desired charge distribution is determined according to methods of drug administration. Examples of pharmaceutically acceptable salts are well known in the art but, without limiting the scope of the present invention, exemplary presentations can be found in the Physician's Desk Reference, The Merck Index, The Pharmacopoeia and Goodman & Gilman's The Pharmacological Basis of Therapeutics.
As used herein and in the appended claims, "TFA" means trifluoro acetic acid, "HCI" means hydrochloric acid, "THF" means tetrahydrofuran, "DMF" means dimethylformamide, "DIPEA" means diisopropylethyl amine, "TMS" means a trimethyl silyl radical and "TBS" means a f-butyldimethyl silyl radical.
As used herein and in the appended claims "leaving group" means halo, oxo, thioxo radicals and activated alcohols such as a p-toluene sulfonyl activated alcohols and other groups that are susceptible to displacement and replacement by a nucleophile under selected conditions of temperature, solvent and time.
As used herein and in the appended claims "scaffold" means a common chemical structure found within a library of organic compounds. Similarly, within a combinatorial chemical library the scaffold forms the basis for a diverse series of chemical derivatization, additions and subtractions. Importantly, regardless of the extent of the chemical derivatization performed on the scaffold, the product is within the scope of the combinatorial library.
All other acronyms and abbreviations have the corresponding meaning as published in journals relative to the art of organic chemistry.
A general method for making polycyclic heterocyles according to the first aspect of the invention involves the following method.
(a) reacting a compound of the formula (I):
Figure imgf000013_0001
where each of R1, R2, R3and R4 is a stable moiety independently selected from the group consisting of halo, haloalkyl, cyano, nitro, Ra-Q-, Ra-Q-alkyl, Ra-Q- alkenyl, Ra-Q-alkynyl, Ra-Q-arylalkyl and Ra-Q-aryl; Ra is hydrogen, alkyl, aryl or arylalkyl;
Q is a single bond, -0-, -NRb-, -CO-, -NRb-CO-, -CO-NRb-, -CO-O-, -O-CO-, S(0)i, -S(O)rNRb-, -NR -S(O)j; i = 0, 1 or 2; j = 1 or 2;
Rb is hydrogen, alkyl, aryl or arylalkyl, where Ra and R may together with the nitrogen to that they are attached form a ring, R5 is selected from the group consisting of halo, nitro, and haloalkyl.
It is understood that each of R1, R2, R3 and R4 may be substituted one to three times with a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, halo, hydroxy, alkoxy, alkylthio, sulfonyl, aryl, heteroaryl and where the substituents of the moieties substituted can themselves be substituted with one to three further substituents, if desired. Particularly one of R , R2, R3 or R4 is an haloalkyl, more particularly either R1, R3 or R4 is a CF3 radical and most particularly R3 is a CF3 radical. Particularly one of R1, R2, R3 or R4 is an hydroxyalkyl, more particularly one of R1, R2, R3 or R4 is methoxy and most particularly R3 is a methoxy radical. Particularly one of R1, R2, R3 or R4 is halo, cyano or nitro. When halo, one of
R1, R2, R3 or R4 is bromo, and most particularly R3 is bromo. When one of R1, R2, R3 or R4 is a cyano radical, R3 is most particularly a cyano radical. When one of R1, R2, R3 or R4 is a nitro radical, R3 is most particularly a nitro radical.
Particularly, R5 is selected from fluoro, chloro or nitro. If a 5,6 polycycle is desired, then R5 is a halo. Also, R5 is between C-\ to Cι2 haloalkyl, particularly R5 is between Ci to C6 haloalkyl and more particularly R5 is a halomethyl and most particularly R5 is bromomethyl.
R6 of formula (I) is selected from the group consisting of cyano and a radical of formula (II) where L is selected from the group consisting of -0-, -S- and -NH-.
Figure imgf000014_0001
When R6 is the radical of formula (II), L is preferably -O- or -S- and most preferably -O-.
R7 of formula (II) is selected from the group consisting of alkyl, aryl, arylalkyl, alkyloxyalkyl, aryloxyalkyl, alkylamino, dialkylamino, arylamino, alkoxy carbonyl, amino, alkoxy, hydroxy and heteroaryl. Where R6 is a radical of formula (II), then R7 is preferably aryl and most preferably R7 is phenyl.
In one embodiment R5 is halomethyl and R6 is cyano. In another embodiment, R5 is halo, R6 is formula (II), L is oxygen and R7 is a phenyl radical. In another embodiment R5 is halo and R6 is cyano.
The compound (I) is reacted with the solid support bound member (III) under suitable conditions for a desired period of time and at a desired temperature such that the compound (I) is reacted with the compound (III). \
N
III Preferably in compound (III), g is a solid support selected from the group consisting of a resin, a polymer, a gel, glass beads, silica gel, a ceramic solid support or other solid composition. More preferably the solid support is a resin and most preferably the solid support is a polystyrene resin.
Likewise in compound (III), h is selected from the group consisting of alkyl and aryl. Preferably h is aryl, more preferably h is a substituted aryl and most preferably h is p-nitrophenyl. Also in compound (III) above, R13 is selected from the group consisting of -
NH-, -O- and -S-, most preferably R13 is -O-.
Suitable conditions for this reaction include having a suitable solvent mixture, a suitable temperature and reacting for a suitable period of time.
A suitable solvent mixture is preferably of basic pH. Preferably the base is an alkoxide, more preferably the base is an alkoxide of fewer than 5 carbons and most preferably the base is K+OBu*. A suitable solvent is either protic or aprotic, preferably the solvent is aprotic and even more preferably the solvent is aprotic and anhydrous and most preferably the solvent is THF.
The reaction temperature is preferably between about 0° C and 85° C but more preferably between about 30° C and about 70° C and most preferably at about 55° C.
The reaction time is preferably between about 1 minute and 2 days, more preferably between about 1 hour and 1 day and most preferably between about 8 hours and 14 hours. Under the above discussed preferred conditions the compounds (I) and (III) react forming an intermediate (IV) where n > 0, and g, h, R1, R2, R3, R4, R6 and R13 are as defined above.
Figure imgf000016_0001
IV
This intermediate (IV) is optionally chemically derivatized prior to the cyclization and displacement procedure.to form a corresponding intermediate (IV):
Figure imgf000016_0002
IV where the R1 , R2 , R3 and R4 substituents are each independently the same as substituents R1, R2, R3 and R4 respectively if not derivatized or are each independently the chemically derivatized substituents respectively. Examples of chemical derivatization reactions include, but are not limited to, the following general derivatizations procedures.
Chemical reaction conditions suitable for BOC (t-butyloxycarbonyl) removal/acylation, TMS (trimethylsilyl) or other silicon based alcohol-protecting group removal (F'/aqueous acid), Mitsunobu reaction (O. Mitsunobu, Synthesis 1981, 1-28), Suzuki coupling (N. Miyaura, A. Suzuki, Chem. Commun. 1979, 866), Horner-Emmons type olefinations \W.S. Wadsworth, Jr., W.D. Emmons, J. Chem. Soc. 83, 1733 (1961)), reductive aminations (Klyeuv and Khidekel, Russ. Chem. Rev. 49, 14-27 (1980)), Sonogashira coupling (S.I. Kahn, M.W. Grinstaff, Tetrahedron Lett. 39, 8031 (1998)), and ester hydrolysis/amidation reaction conditions. Specific examples of the above described chemical derivatization of the intermediate are in the included examples. The BOC protected nitrogen of the intermediate compound of Example ix is deprotected and reacted with acetic anhydride. The TBS (f-butyldimethyl silyl) protected alcohol of the intermediate compound of Example x is deprotected with tetrabutylamonium fluoride and reacted with a chlorophenol under Mitsunobu conditions to give the p-chlorophenyl ether derivatized intermediate. The methylene ester radical at R3 of the intermediate of Example xv is subjected to ester hydrolysis/amidation providing the p-chlorophenyl methylaminocarbonyl methylenamide substituent.
Although optional, examples of preferred derivatizations are as discussed above, and as described in Scheme B.
Figure imgf000018_0001
Scheme B After the optional derivatization of the intermediate, the cyclization and displacement reaction whereby the product (V) is formed.
Figure imgf000019_0001
V
In product (V), the R' , R , R° and R4 substituents are each independently the same as substituents R1, R2, R3 and R4 respectively if not derivatized or are each independently the chemically derivatized substituents respectively. Hence, each of R1 , R2 , R3 and R4 may be correspondingly the same as R1, R2, R3 and R4 or may represent the result of the optional chemical derivatization of the corresponding substituent, prior to cyclization and displacement. Also, chemical derivatization includes other ring formation or ring closure reactions such as where any two of R1 , R2 , R3 and R4 together form an aryl or an alkyl ring of between about 5 and 14 atoms.
R7 is amino, hydroxy or the same as R7 above.
CONDITIONS SUITABLE FOR THE CYCLIZATION AND DISPLACEMENT PROCEDURE
The temperature for the cyclization and displacement procedure may be between about 0° and 85° C but is preferably between about 30° and 70° and is most preferably at about 55° C.
The solvents suitable for the cyclization and displacement procedure include protic and aprotic solvent mixtures, aqueous and anhydrous solvent mixtures. A preferred solvent is TFA, a more preferred solvent mixture is TFA:H O a most preferred solvent mixture is TFA:5 N HCI/H20. Although a solvent mixture of TFA:5 N HCI/H2O is most preferred, the ratio of this TFA:5 N HCI/H2O mixture may vary between about 1 :1 to about 99:1 TFA:5 N HCI/H20, but preferably is between about 80:1 to 1 :1 TFA:5 N HCI/H2O, and is most preferably at about 4:1 TFA:5 N HCI/H2O. The time for the cyclization and displacement reaction may vary, but generally is between about 1 minute and 4 days but preferably between about 1 hour and 20 hours.
A second aspect of the invention is directed to a solid support bound intermediate (IV) above. Optionally, the intermediate (IV) can be derivatized before the cyclization and displacement procedure to thereby provide further options for the groups R1, R2, R3 and R4 in the final product. The preferred, yet optional, derivatizations of the intermediate compound (IV), and preferred conditions whereby optional derivatizations occur are as described above.
A third aspect of the invention is directed to a library of polycyclic heterocycle compounds where the library contains a plurality of diverse compounds (V):
Figure imgf000020_0001
V
In compound (V), where each of R1, R2, R3 and R4 is a stable moiety independently selected from the group consisting of halo, haloalkyl, cyano, nitro, Ra-Q-, Ra-Q-alkyl, Ra-Q- alkenyl, Ra-Q-alkynyl, Ra-Q-arylalkyl and Ra-Q-aryl;
Ra is hydrogen, alkyl, aryl or arylalkyl;
Q is a single bond, -O-, -NRb-, -CO-, -NRb-CO-, -CO-NRb-, -CO-O-, -O-CO-, S(0)i, -S(O)rNRb-, -NRb-S(O)j; i = 0, 1 or 2; j = 1 or 2;
Rb is hydrogen, alkyl, aryl or arylalkyl, where Ra and Rb may together with the nitrogen to that they are attached form a ring, and n > 0; and R7 is selected from the group consisting of alkyl, aryl, arylalkyl, alkyloxyalkyl, aryloxyalkyl, alkylamino, dialkylamino, arylamino, alkoxy carbonyl, amino, alkoxy, hydroxy and heteroaryl; and
R13 is selected from the group consisting of -NH-, -O- and -S-. Preferred substituents for R1 , R2 , R3, R4 , R7 , and values for n are as described above, in the included examples and the appended claims.
A fourth aspect according to the present invention preferably produces a library of compounds where the compounds comprise a diverse chemical library according to the general methods discussed above. All of the compounds in such a library have a common scaffold, e.g., compound (V).
When preparing a combinatorial library according to the present invention, diversity is introduced via the R1', R2 , R3 , R4 , R7, and R13 substituents as discussed more fully above. These substituents are selected to allow the creation of a chemically diverse library that, as one goal, maximizes the exploration of molecular spatial properties. Such maximization increases the likelihood of creating compounds that will be biologically active against selected targets.
A fifth aspect of the invention is directed to an assay kit for the identification of biologically active compounds, the kit comprising assay materials and a well plate apparatus where each well in the apparatus contains a compound of the library described above.
PARALLEL SYNTHESIS
The fourth and fifth aspects of the solid support mediated method of the invention may be carried out by way of parallel synthesis in any reaction vessel capable of holding the liquid reaction medium and having, preferably, inlet and outlet means.
For small-scale synthesis of multiple products, the solid support mediated method of the invention is preferably carried out in containers adaptable to parallel array syntheses. With parallel array synthesis, individual reaction products are prepared in each of multiple reaction zones. The reaction zones are physically separated from one another in a reaction vessel. Compounds can be added to the reaction vessel by multiple delivery apparatus, automated or robotic apparatus, any of that may be either manually or computer controlled.
A preferred parallel synthesis embodiment of the present invention is a diverse polycyclic heterocycle compound library in the form of a plurality of wellplates, each wellplate having wells containing a separate reaction product (library compound). In such cases, their wellplate number and "x" column and "y" wellplate row coordinates conveniently identify the library compounds. The process of making the library of polycyclic heterocycle compounds may be conveniently carried out in a conventional wellplate apparatus. It is particularly advantageous to carry out the method of the invention in a standard wellplate apparatus such as a plastic 96 well microtiter plate.
Typically, the wellplate apparatus is in the form of a rigid or semi-rigid plate, the plate having a common surface containing openings of a plurality of reservoirs arranged in rows and columns. A standard form of wellplate apparatus is a rectangular plastic plate having 8 rows and 12 columns (total 96) of liquid retaining depressions, or reservoirs, on its surface. A wellplate apparatus may optionally have other elements of structure such as a top or cover (e.g., plastic or foil), a bottom in a form such as a plate or reservoir, clamping means to secure the wellplate and prevent loss of its contained compounds.
The polycyclic heterocycle library of compounds formed using the solid support mediated method aspects of the invention can be used to screen compounds for biological or other activity. Myriad biological assays are known in the art and can be used to screen the polycyclic heterocycle library of compounds.
SCREENING OF POLYCYCLIC HETEROCYCLE DERIVATIVE LIBRARIES
The libraries of diverse polycyclic heterocycle according to the solid support mediated method of the present invention (e.g., compounds (II)) may be screened for biological activity. Generally the library to be screened is exposed to a biological substance, usually a protein such as a receptor, enzyme, membrane binding protein or antibody, and the presence or absence of an interaction between the heterocycle derivative and the biological substance is determined. Typically this will comprise determining whether the biological substance is bound to one or more of the members of the library. Such binding may be determined by attaching a label to the biological substance. Commonly used labels include fluorescent labels. Other methods of labeling may be used, such as radioactive labels. The degree of binding affinity may be determined by quantitating the amount or intensity of the bound label. Thus, various biologically active compounds may be selected by identifying that compounds bind the particular biological substance most effectively. Illustrative additional assays include but are not limited to in vitro assays such as enzymatic inhibition, receptor - ligand binding, protein - protein interaction, andprotein - DNA interaction; cell based, functional assays such as transcriptional regulation, signal transduction / second messenger, and viral infectivity; add, incubate & read assays such as scintillation proximity assays (SPA), fluorescence polarization assay, fluorescence correlation spectroscopy, colorimetric biosensors, cellular reporter assays using reporter genes such as luciferase, green fluorescent protein, β-lactamase, and the like; and electrical cell impedance sensor assays.
All of the above assays are known in the art to be predictive of success for an associated disease state.
EXAMPLES
The following examples are provided as illustration only, and are not intended to limit this invention in any way.
General. Reagents obtained from commercial sources were used without further purification. Kaiser oxime resin 1 was purchased from Novabiochem with a loading capacity of 1.07 mmol/g. All NMR spectra (400 MHz) were recorded on a Varian Gemini-400 spectrometer. Mass spectra were obtained with either ESI or FAB as the ionization method. All purifications were carried out by radial chromatography (Chromatotron® model 8924, Harrison Research) using 1 mm silica gel plates (Analtech). Crude purities were estimated from integrated peak areas of HPLC chromatographs with the UV detector monitoring at λ = 215 nm. Analytical HPLC setup: C-is Vydac® column with solvent gradient A = acetonitrile (0.1% TFA) and B = water (0.1% TFA) at 1 ml/min flow-rate. Unless otherwise noted, all HPLC retention times are given for an eluent gradient of 10% A to 60% A over 40 min. The nomenclature of 3-aminobenzisoxazole compounds is based on the heterocycle numbering system (Shutske, G.M.; Kapples, K.J. J. Heterocyclic Chem. 1989, 26, 1293. For other examples of solution phase intramolecular nucleophilic additions to nitrile by nitrogen see: Kwok, R.; Pranc, P. J. Org. Chem. 1967, 32, 738. Blicke, F.F.; Zambito, A.J.; Stenseth, R.E.; J. Org. Chem. 1961, 26, 1826.) shown below:
Figure imgf000024_0001
Table A lists representative moieties that are substituted for R on the designated position of the starting compound. Because the moieties are representative of a general class of organic substituents, it is meant that other organic substituents are chemically equivalent to those given in Table A and are within the scope of the invention and appended claims. For example, where the CF3 radical replaces R3, the placement of the same group in position 4, 5 or 6 is an equivalent analogue. Hence, the CF3 placed at each of positions 3, 4, 5, 6 or any combination thereof is within the scope of this invention and appended claims. Furthermore the CF3 group is, optionally, meant to represent an electron withdrawing group and can therefor be replaced by other electron withdrawing groups such as polyhalo-alkyl and be within the scope of this invention.
Although not wanting to be bound by a theoretical explanation of chemical mechanistic analysis, the following proposed mechanism is useful for explaining an embodiment of the invention.
Figure imgf000025_0001
In the proposed mechanism, the solid support bound oxime is reacted with the fluorobenzonitrile of Example 1 under suitable conditions to form the solid support bound intermediate. The solid support bound intermediate is optionally isolated and finally subjected to the cyclization and displacement procedure. As illustrated in Scheme III, the nitrogen and oxygen of the solid support bound oxime are involved in the cyclization and displacement reaction and become part of the polycyclic heterocycle.
Table A
Example R % yield of the resin % isolated yield of the
Number bound intermediate corresponding R substituted benzisoxazoles i H 64 76 ii R4=CF3 83 62 iii R3=MeO 80 85 iv R3=CF3 90 86
V R3=Br - 90 78 vi R3=CN 69 68 vii R1=CF3 69 75
Figure imgf000026_0001
Although not limited to these exemplary reactions, it will become apparent to one of skill in the art through these examples and appended claims the broad range of chemical derivations and transformations that can, optionally, be performed on the solid support bound intermediate. The optional chemical derivatization of the solid support bound intermediate according to a broad range of chemistry with neither destruction of the solid support nor diminishment of the derivatized polycyclic heterocycle yield is a surprising result. Indeed, it is within the scope of this invention to allow the optional chemical derivatization of the solid support bound intermediate according to methods known in the art.
Although Table A demonstrates some examples, it is to be understood that the solid support mediated method according to one aspect of this invention includes analogues involving substituents at each available position of the aromatic scaffold, such as a tri or tetra substituted phenyl. Moreover, where R is methoxy, then a Ci to Cι2 alkoxy is considered an equivalent analogue. And where the substituent group is Br, then another halo substituent such as -F or -CI is an equivalent analogue.
The solid support mediated method according to the present invention further allows for the optional chemical derivatization of none, any, or all of R1, R2, R3 R4 substituents of the solid support bound intermediate as provided above. Indeed the solid support bound intermediate is preferably stable to a broad range of reaction conditions.
Table B lists substituted aromatic compounds (I), which are reacted with the solid support bound member, thereby forming the solid support bound intermediate (IV), are chemically derivatized with final cyclization and displacement of the corresponding polycyclic heterocycle.
Figure imgf000027_0001
I
The compounds of Table B are synthesized according to the solid support mediated method of the present invention. This list is intended to demonstrate the diversity of compounds that are synthesized according to this invention and is not intended to limit the scope in any way.
Table B
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000029_0002
Figure imgf000030_0001
Figure imgf000030_0002
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000032_0002
Figure imgf000033_0001
Figure imgf000034_0002
Figure imgf000034_0001
The resin bound intermediates of the present invention were surprisingly stable to conditions suitable for optional derivatizations such as, BOC removal/acylation, TBS removal and Mitsunobu coupling, Suzuki coupling, Sonogashira coupling, Hoerner-Emmons olefination, and ester hydrolysis/amidation reaction conditions. These and other reactions discussed were performed according to the following detailed chemical procedure.
General Synthetic Procedures
The following general synthetic procedures where used to synthesize the above mentioned products. Although the following procedures are specific to the formation of an intermediate and product with a designated "R" group, the desired intermediate and product can be obtained through replacement of the desired "R" group for the one designated in the procedure.
General Example 1
Formation of 3-aminobenzisoxazole : to 500 mg of high loading (1.07 mmol/g, 0.54 mmol) p-nitrobenzophenone oxime polystyrene resin (obtained from Novabiochem) in a 25 mL capacity Kontes Microfilter Funnel is added 7 mL of THF and 640 μL of potassium -butoxide (1 M in THF, 0.642 mmol). This was shaken by hand for several minutes whereupon the resin turned a purple color. To this was added 2-fluorobenzonitrile (1.07 mmol, 214 mg) neat. The reaction vessel is placed in an oven fitted with a rotating device for 12 h. The oven was at the most preferred temperature of 55° C. The loaded resin was removed from the oven and allowed to cool for 1 h and rinsed with 2 x 5 mL of CH2CI2, 2 x 5 mL of 5% TFA/CH2CI2, 2 x 5 mL of isopropanol and 4 x 5 mL of MeOH. This was dried in a 35° C vacuum oven for 12 h. Next, 4 mL of TFA and 1mL of aqueous 5 N HCI were then added to the resin followed by turning for 2 h in a 55° C oven. The TFA/H2O was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. These were combined and concentrated in vacuo to give the crude product (>98% purity by reverse phase HPLC) that was radial chromatographed on a 2 mm plate using 25% EtOAc/Hexanes. Concentration of the product containing fractions gave pure (35 mg, 2 step yield = 49%, 74% yield based on loading).
General Example 2 Formation of 4-amino-1 H-2,3-benzoxazine : to 500 mg of high loading
(1.07 mmol/g, 0.54 mmol) p-nitrobenzophenone oxime polystyrene resin (obtained from Novabiochem) in a 25 mL capacity Kontes Microfilter Funnel was added 7 mL of THF and 640 μL of potassium f-butoxide (1 M in THF, 0.642 mmol). This was shaken by hand for several minutes whereupon the resin turned a purple color. To this was added 2-(1-bromomethyl)benzonitrile (1.07 mmol) neat. The reaction vessel was placed in an oven fitted with a rotating device for 12 h. The oven was at the most preferred temperature of 55° C. The loaded resin was removed from the oven and allowed to cool for 1 h and rinsed with 2 x 5 mL of CH2CI2, 2 x 5 mL of 5% TFA/CH2CI2, 2 x 5 mL of isopropanol 4 x 5 mL of MeOH. This was dried in a 35° C vacuum oven for 12 h. Next, 4 mL of TFA and 1mL of aqueous 5 N HCI were then added to the resin followed by turning for 8 h in a 55° C oven. The TFA/H2O was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. These were combined and concentrated in vacuo to give the crude product (>98% purity by reverse phase HPLC) that was radial chromatographed on a 2 mm plate using 25% EtOAc/Hexanes. Concentration of the product containing fractions gave pure product.
General Example 3
Formation of 3-amino-6- (N-acetylaminomethyl) benzisoxazole: to 500mg of high loading (1.07 mmol/g, 0.54 mmol) p-nitrobenzophenone oxime polystyrene resin (obtained from Novabiochem) in a 25 mL capacity Kontes Microfilter Funnel was added 7 mL of THF and 640 μL of potassium f-butoxide (1 M in THF, 0.642 mmol). This was shaken by hand for several minutes whereupon the resin turned a purple color. To this was added 4-(N-BOC-aminomethyl)-2- fluorobenzonitrile (1.07 mmol, 214 mg) neat. This reaction vessel was placed in a 55 °C oven fitted with a rotating device for 12 h. This was removed from the oven and allowed to cool for 1 h and rinsed with 2 x 5 mL of CH2CI2, 2 x 5 mL of isopropanol, and 4 x 5 mL of isopropanol, and 4 x 5 mL of MeOH. This was dried in a 35 °C vacuum oven for 12 h. BOC-deprotection was achieved using 25% TFA/CH2CI2 (7 mL) followed by shaking for 2 h. Resin was again rinsed with 2 x 5 mL of CH2CI2, 2 x 5 mL of isopropanol, and 4 x 5 mL of MeOH. The resin was suspended in DMF followed by addition of acetic anhydride and diisopropylethylamine. This was allowed to shake for 3h and was rinsed with 2 x 5 mL of CH2CI2, 2 x 5 mL of isopropanol, and 4 x 5 mL of MeOH. 4 mL of TFA and 1 mL of aqueous 5 N HCI were then added to the resin followed by turning for 2 h in a 55° C oven. The TFA/H2O was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. These were combined and concentrated in vacuo to give the crude benziosoxazole product (98% purity by reverse phase HPLC) that was radial chromatographed on a 2 mm plate using 25% EtOAc/Hexanes. Concentration of the product containing fractions gave pure benzisoxazole product (35 mg, 4 step yield = 49%).
General Example 4
Formation of 3-amino-6- (p-chlorophenoxymethyl) benzisoxazole: to 500mg of high loading (1.07 mmol/g, 0.54 mmol) p-nitrobenzophenone oxime polystyrene resin (obtained from Novabiochem) in a 25 mL capacity Kontes Microfilter Funnel was added 7 mL of THF and 640 μL of potassium f-butoxide (1 M in THF, 0.642 mmol). This was shaken by hand for several minutes whereupon the resin turned a purple color. To this was added 4-(tetf-butyldimethylsilyloxymethyl)-2- fluorobenzonitrile (1.07 mmol, 214 mg) neat. This reaction vessel was placed in a 55 °C oven fitted with a rotating device for 12 h. This was removed from the oven and allowed to cool for 1 h and rinsed with 2 x 5 mL of CH2CI2, 2 x 5 mL of isopropanol, and 4 x 5 mL of MeOH. This was dried in a 35 °C vacuum oven for 12 h to give a Δwt = 82 mg (63% loading yield).TBS-deprotection was achieved using 1 M TBAF in THF (1.07 mL, 2 equiv.) followed by shaking for 18 h. The resin was rinsed with 2 x 5 mL of CH2CI2, 2 x 5 mL H2O, 4 x 5 mL of MeOH. This was dried in a 35° C vacuum oven for 12 h. The resin was suspended in 8 mL of 1:1 THF/CH2CI2 followed by addition of triphenylphosphine (700mg, 5 equiv.) and 4-chlorophenol (690 mg, 10 equiv.). This was shaken by hand followed by the slow addition of diisopropyl azodicarboxylate (0.53mL 5 equiv). This was allowed to shake for 3h and was rinsed with 2 x 5 mL of MeOH, 2 x 5 mL H2O, and 4 x 5 mL of MeOH. 4 mL of TFA and 1 mL of aqueous 5 N HCI were then added to the resin followed by turning for 2 h in a 55 °C oven. The TFA/H2O was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. These were combined and concentrated in vacuo (68% purity by reverse phase HPLC) that was radial chromatographed on a 2 mm plate using 25% EtOAc/Hexanes. Concentration of the product containing fractions gave pure benzisoxazole (49 mg, 4 step yield = 33%).
General Example 5 Loading Reaction. Nucleophilic aromatic substitution reactions have been extensively studied in solution. (Nudelman, N; Mancini, P.M.E.; Martinez, R.D.; Vottero, L.R. J. Chem. Soc. Perkin Trans. 2 1987, 951. Miller, J. "Aromatic Nucleophilic Substitution"; Elsevier: Amsterdam, 1968. Bernasconi, CF. Ace. Chem. Res. 1978, 77, 147) However, the extent to that this precedent could be applied to predict the outcome of these heterogenous reactions was not clear given the importance of resin swelling properties, site accessibility, etc. (Yan, B; Fell J. B.; Gnanasambandam, K. J. Org. Chem. 1996, 61, 7467.) Therefore, we studied the effect of the solvent, leaving group, and counterion on the solid phase loading reaction (Table 1). In comparing THF, MeCN, DMF, and DMSO, THF gave the best results, providing a 68% loading yield with 2-fluorobenzonitrile (2a) and 72% with 2-nitrobenzonitrile (2b). (Palermo, M.G. Tetrahedron Lett. 1996, 37, 2885.) A 20 to 30% decrease in the loading yield was observed for both 2a and 2b when DMF or DMSO was used as the solvent. Loading yields also decreased dramatically with the use of chloro- (2c), bromo- (2d), and iodo- (2e) benzonitriles.
The effect of the counterion on the loading reaction was evaluated with 2- fluorobenzonitrile as the substrate in THF (Table 1 , entry 1). The potassium salt of resin 1 gave the highest loading yields with potassium fetf-butoxide (KOBu1) giving slightly better results than potassium hexamethyldisilazide (KHMDS). Treatment of 1 with sodium hexamethyldisilazide (NaHMDS), gave a loading yield of 42% and, interestingly, no loading was observed with lithium hexamethyldisilazide (LiHMDS). As described above, a variety of 2-fluorobenzonitriles can be loaded on the Kaiser resin (Lepore, S.D.; Wiley, M.R. J. Org. Chem. 1999, 64, 4547.). Although the presence of an electron withdrawing group facilitates loading at room temperature, substrates bearing either electron withdrawing groups or electron donating groups can be loaded in high yield in about 2 h at 55 °C. We also found that the loading reaction of 2-fluorobenzonitriles is not particularly sensitive to steric hindrance around the site of nucleophilic substitution.
Table 1. Effect of leaving group, solvent, and counterion on loading reactions.
Figure imgf000040_0001
% loading yield of 3ε entry base THF MeCN DMF DMSO
KOBu* 68 13 41 47
KHMDS 55
NaHMDS 42
LiHMDS <5
NO2 KOBu* 72 28 41 54
CI KOBu4 <5 <5 <5 15
4 Br KOBu* <5
KOBu <5
'Determined by resin weight difference (average of 3 experiments)
General Example 6
Studies on the acid stability of the aryl oxime linker. As previously reported, the use of 4:1 TFA/aqueous 5 N HCI at 55 °C for 2 h (Table 2, Method A) led to an efficient cyclorelease of a variety of substituted aminobenzisoxazoles. By contrast, we saw that the use of 99:1 TFA/H2O at 55 °C (Table 2, Method B) with intermediates bearing either inductively neutral or electron withdrawing substituents required significantly longer reaction times to reach completion. For example, hydrolysis of the resin bearing a bromo substituent para to the nitrile (Table 2, entry 2) using Method B required 4 days to give the corresponding aminobenzisoxazole 4b in 65% yield. On the other hand, treatment of the para-methoxybenzonitrile derivative 3c (Table 2, entry 3), under the same conditions, gave the methoxy- substituted product 4c in 87 % isolated yield after only 2 h.
While the studies summarized above were important for identifying useful cyclorelease conditions, further experiments were performed in order to determine the acid stability profile of the linker under a variety of conditions commonly used for the removal of acid-sensitive protecting groups. The methoxy-substituted resin 3c was selected for this study, since it is the most acid labile and therefore represents the worst case scenario. Upon treatment of the methoxy-substituted resin 3c with 25% anhydrous TFA/CH2CI2 at room temp for 2 h (Table 2, entry 3, Method C), conditions precedented for on-resin Boc removal, <5% of the cyclization product 4c was removed from the resin. Even under more forcing conditions, with 100 % anydrous TFA at 55 °C (Table 2, entry 3, Method D) only 9% of the 3-aminobenzisoxazole product (>96% purity) was removed from the resin after 2 h. The aryl oxime linker was also stable to a number of milder aqueous acidic conditions that have been used for the removal of THP, silyl, and acetal protecting groups in solution. Thus, treatment of the resin 3c with AcOH THF/H2O (3/1/1) at 55 °C for 12h (Corey, E.J.; Venkateswarlu, A. J. Am. Chem. Soc, 1972, 94, 6190.) (Table 2, entry 3, Method E), or with TsOH/THF/H2O at 55 °C for 12h (Thomas, E.J.; Williams, A.C. J. Chem. Soc. Chem. Comm., 1987, 992.) (Table 2, entry 3, Method F) gave no detectable release of material from the resin. Table 2. Acid stability profile of the aryl oxime linker.
Figure imgf000042_0001
4a(X = H)
3a(X = H) 4b(X = Br) 3b(X = Br) 4c(X = OMe) 3c(X = OMe)
entry X product method3 yieldb (time) (% purity)
Figure imgf000042_0002
'Method A = 4: 1 TFA/5N HCI, 55 °C. Method B = 99: 1 TFA/H20, 55 °C. Method C = 25% THF/CH2C12, room temp. Method D = TFA, 55 °C. Method E = AcOH/THF/H20, 55 °C. Method F = TsOH/THF/H20, 55 °C. isolated yield after chromatography and based on loading. Crude purity based on HPLC analysis.
General Example 7
Amide bond formation. Due to the importance of solid phase peptide synthesis, amide bond forming reactions have been the most widely performed and most highly developed solid phase reactions. (Kaldor, S.W.; Siegel, M.G. Comb. Chem. Mol. Diversity Drug Discovery 1998, 307-335. Editors: Gordon, Eric M.; Kerwin, James F., Jr. Publisher: Wiley-Liss, New York, N. Y.) We have previously shown above that amides can be formed in the presence of an aryl oxime linker by the reaction of an acid chloride or an acid anhydride with an aryl oxime-linked benzylamine. In the present study, we set out to demonstrate that an aryl oxime- linked acid could be coupled to an amine under standard peptide coupling conditions. By proceeding through the intermediacy of methyl ester 5, we also sought to demonstrate the compatibility of the aryl oxime linker with the aqueous basic conditions required for saponification (Scheme 2). Thus, the potassium anion of the Kaiser resin 1 as coupled with methyl 3-fluoro-4-cyanobenzoate to give resin 5 in a 69% loading yield. Treatment of resin 5 with LiOH, in THF/MeOH/H2O (3/1/1) at room temperature gave the corresponding acid (6) and no removal of the substrate from the resin was observed, demonstrating the stability of the aryl oxime linker under these conditions. Acid 6 was then coupled to 4-chlorobenzylamine to give the on-resin amide. Both the resin weight increase and chlorine analysis of the intermediate suggested that the coupling reaction went essentially to completion within 12 h. The resin was then treated with the standard cyclorelease conditions to give the desired amide 7 in a 3 step yield of 81% (93% crude purity).
Scheme 2. On-resin hydrolysis and amide bond formation.
Figure imgf000044_0001
Figure imgf000044_0002
isolated yield = 81% crude purity = 93%
Synthesis of 6-[(p-chlorophenyl)methylaminocarbonyl]-3-amino-1 ,2- benzisoxazole (7): to p-nitrobenzophenone oxime polystyrene (Kaiser) resin (500 mg, 1.07 mmol/g, 0.54 mmol) in a tared 25 mL Kontes Microfilter Funnel was added THF (7 mL) and potassium f-butoxide (640 μL, 1 M in THF, 0.642 mmol). After shaking by hand for several minutes, the resin turned a deep purple color. To this suspension was added 2-fluoro-4-(methoxycarbonyl)benzonitrile (1.07 mmol, 192 mg). The reaction vessel was rotated at 55 °C in a Robbins oven for 12 h to give resin 5 followed by cooling for 1 h. The resin was then rinsed with 2 x 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 x 5 mL of H20, and 4 * 5 mL of MeOH. The resin was dried in a 35 °C vacuum oven for 12 h to give a Δwt = 50.0 mg (58% loading yield). To effect ester hydrolysis, the resin was then suspended in THF (7 mL) followed by the addition of LiOH (39 mg, 1.61 mmol) dissolved in MeOH/H2O (1 :1 , 2 mL) and rotated at room temp, for 12 h. The resin was then rinsed with 2 * 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 x 5 mL of H2O, 2 x 5 mL of MeOH, and 2 x 5 mL of DMF. The resin was then suspended in DMF (7 mL) and to this was added p- chlorobenzylamine (261 μL, 2.14 mmol), 1-hydroxybenzotriazole hydrate (HOBt) (289 mg, 2.14 mmol), benzotriazole-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (947 mg, 2.14 mmol), and diisopropylethylamine (DIPEA) (467 μL, 2.68 mmol). The reaction was allowed to proceed for 12 h at room temp. The resin was then rinsed 2 5 mL of CH2CI2, 2 5 mL of MeOH, 2 x 5 mL of H20, and 4 5 mL of MeOH. The resin was dried in a 35 °C vacuum oven for 12 h to give a Δwt = 84 mg. TFA (4 mL) and 5 N HCIaq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven. The TFA/HCIaq was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. These washings were combined and concentrated in vacuo to give the crude product 7 (93% purity by reverse phase HPLC) that was purified by radial chromatography on a 2 mm plate eluting with 50% EtOAc/Hexanes. Concentration of the product containing fractions gave pure 6-[(p-chlorophenyl)-methylaminocarbonyl]-3-amino-1 ,2-benzisoxazole (7) (76 mg, 3 step yield = 81% based on the ester loading yield): HPLC retention time (eluent gradient 10%A to 60%A over 45 min) = 24.9 min. 1H NMR (400 MHz, DMSO- d6) δ 9.19 (t, J = 5.6 Hz, 1 H), 7.84 - 7.91 (m, 2H), 7.72 (dd, J = 8.0, 1.2 Hz, 1H), 7.37 - 7.31 (m, 4H), 6.50 (bs, 2H), 4.45 (d, J = 6.0 Hz, 2H). MS (ESI) m/z 300 [35CI, (M+H)+], 302 [37CI, (M+H)+]. HRMS Calcd for C17H15N203 295.1083, found 295.1079.
General Example 8
Phenolic Mitsunobu reaction. On-resin carbon-oxygen bond formation via the Mitsunobu reaction has been identified as an important tool in combinatorial chemistry (Kaldor, S.W.; Siegel, M.G. Comb. Chem. Mol. Diversity Drug Discovery 1998, 307-335. Editors: Gordon, Eric M.; Kerwin, James F., Jr. Publisher: Wiley- Liss, New York, N. Y). Application of this reaction to an aryl oxime-linked substrate is shown in Scheme 3. Resin 8 was prepared by reacting the potassium anion of the Kaiser resin 1 with 2-fluoro-4-( -butyl-dimethylsilyloxymethyl)-benzonitrile. The TBS- protecting group was removed using TBAF in THF. The on-resin alcohol was then treated with p-chlorophenol, triphenylphosphine and diisopropylazodicarboxylate (DIAD) in THF. (Krchnak, V.; Flegelova, Z.; Weichsel, A.S.; Lebl, M. Tetrahedron Lett. 1995, 38, 3345.) The best results were observed for reactions times of 3 h. Longer reaction times generally led to decreased purity in the crude cyclization product. Cyclitive removal using the standard conditions then gave aryl ether 9 in a 77% yield (3 steps) and 83% crude purity.
Scheme 3. On-resin Mitsunobu reaction.
Figure imgf000046_0001
Synthesis of 6-[(p-chlorophenyl)oxymethyl]-3-amino-1 ,2-benzisoxazole (9): to p-nitrobenzophenone oxime polystyrene (Kaiser) resin (500 mg, 1.07 mmol/g, 0.54 mmol) in a tared 25 mL Kontes Microfilter Funnel was added THF (7 mL) and potassium f-butoxide (640 μL, 1 M in THF, 0.642 mmol). After shaking by hand for several minutes, the resin turned a deep purple color. To this suspension was added 2-fluoro-4-(tett-butyldimethylsilyloxymethly)-benzonitrile (1.07 mmol, 285 mg). The reaction vessel was rotated at 55 °C in a Robbins oven for 12 h to give resin 8 followed by cooling for 1 h. The resin was then rinsed with 2 x 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 x 5 mL of H2O, and 4 x 5 mL of MeOH. The resin was dried in a 35 °C vacuum oven for 12 h to give a Δwt = 71.1 mg (54% loading yield). To effect TBS removal, the resin was then suspended in THF (6 mL) followed by the addition of TBAF (562 μL, 1 M in THF, 0.562 mmol) and rotated at room temperature for 12 h. The resin was then rinsed with 2 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 x 5 mL of H2O, 2 5 mL of MeOH, and 2 5 mL of CH2CI2. The resin was then suspended in CH2CI2 (7 mL) and to this was added p-chlorophenol (690 mg, 5.35 mmol), triphenylphosphine (700 mg, 2.68 mmol), and diisopropyl-azodicarboxylate (DIAD) (530 μL, 2.68 mmol). The reaction was allowed to proceed for 1 h at room temp. The resin was then rinsed 2 5 mL of CH2CI2, 2 5 mL of MeOH, 2 x 5 mL of H2O, and 4 5 mL of MeOH. The resin was dried in a 35 °C vacuum oven for 12 h. TFA (4 mL) and 5 N HCIaq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven. The TFA/HCIaq was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. These washings were combined and concentrated in vacuo to give the crude product 7 (83% purity by reverse phase HPLC) that was purified by radial chromatography on a 2 mm plate eluting with 50% EtOAc/Hexanes. Concentration of the product containing fractions gave pure 6-[(p- chlorophenyl)oxymethyl]-3-amino-1 ,2-benzisoxazole (9) (61 mg, 3 step yield = 77% based on loading yield): HPLC retention time (eluent gradient 10%A to 60%A over 45 min) = 37.5 min. 1H NMR (400 MHz, DMSO-d6) δ 7.73 (d, J = 8.0 Hz, 1 H), 7.84 - 7.91 (m, 2H), 7.72 (dd, J = 8.0, 1.2 Hz, 1 H), 7.44 (s, 1 H), 7.30 (d, J = 8.0 Hz, 1 H), 7.25 - 7.21 (m, 2H), 6.99 - 6.95 (m, 2H), 5.17 (bs, 2H), 1.22 (d, J = 6.4 Hz, 2H). MS (ESI) m/z 274 [35CI, (M+H)+], 276 [37CI, (M+H)+]. Anal Calc'd for C14H11CIN2O2: C, 61.21 ; H, 4.04; N, 10.2; CI, 12.91. Found: C, 61.08; H, 4.32; N, 10.19; CI, 12.47.
General Example 9
On-resin nucleophilic aromatic substitution. Recently, examples of on- resin nucleophilic aromatic displacement reactions have appeared in the literature. (Wijkmans, J.C.H.M.; Culshaw, A.J.; Baxter, A.D. Mol. Diversity 1998, 3, 117.) In order to evaluate the compatability of the aryl oxime linker with this reaction, a resin-attached fluorobenzonitrile (10) was prepared (Scheme 4). In order to avoid any regioselectivity issues in the loading reaction, the symmetrical 2,6- difluorobenzonitrile was chosen for this initial investigation. Resin 10 was then reacted with a variety of nucleophiles including an alkoxide (Plenkiewicz, H.;
Dmowski, W. J. Fluorine Chem. 1998, 89, 213.), amine (Morales, GA; Corbett, J.W.; DeGrado, W.F. J. Org. Chem. 1998, 63, 1172. Vojkovsky, T.; Weichsel, A.; Patek, M. J. Org. Chem. 1998, 63, 3162. Dankwardt, S.M.; Newman, S.R.; Krstenanski, J.L. Tetrahedron Lett. 1995, 36, 4923.), and phenol (Kiselyov, A.S.; Eisenberg, S.; Luo, Y Tetrahedron Lett. 1999, 40, 2465.. Burgess, K; Lim, D.; Bois-Choussy, M.; Zhu, J. Tetrahedron Lett. 1997, 38, 3345.)) (Table 3). The potassium alkoxide of 4-chlorophenethanol (Table 3, entry 1) was prepared by treatment with 2 equivalents potassium f-butoxide. This salt was then added to a THF suspension of resin 10 to give the corresponding product 11a after cyclorelease in a two step yield of 50%.
Scheme 4. Regioselective synthesis of 6-fluoro-3-aminobenzisoxazole.
Figure imgf000048_0001
cru * Vf* > 96% isolated yield = 74%
Figure imgf000048_0002
Table 3. On-resin nucleophilic aromatic substitution.
Figure imgf000049_0001
entry nucleophile & product yield3 J conditions (% purity)
Figure imgf000049_0002
"Isolated yield after chromatography and based on loading.
Crude purity based on HPLC analysis. bMajor impurity was the unreacted fluorine product
(4-fluoro-3-aminobenzisoxazole)
Addition of pyrrolidine to 10 proved more challenging (Table 3, entry 2). In our initial attempt (THF, 6 h, 55 °C) the desired product 11b was produced in low isolated yield as a result of incomplete displacement. The major impurity in this reaction was 4- fluoro-3-aminobenzisoxazole, the cyclization product of the unreacted starting material (10). In an attempt to increase the rate of the SNAr reaction in THF, variations in the reaction time, number of equivalents of nucleophile, and the temperature were evaluated. Significant improvements were obtained with the use of alternate solvents. Although only a slight improvement was observed with acetonitrile (studies on the fluorine kinetic isotope effect in SNAΓ reactions with aryl fluorides have shown that the use of acetonitrile as the reaction solvent leads to a different rate limiting step in the overall mechanism when compared with THF. Persson, J.; Axelsson, S.; Matsson, O. J. Am. Chem. Soc. 1996, 118, 20.), both DMF and DMSO produced a significant increase in the reaction rate. After 6 h at 55 °C in DMSO, followed by the cyclorelease reaction, compound 11b was obtained in 94 % crude purity and subsequently isolated in 80 % yield.
Similar to the pyrrolidine SNAΓ reaction discussed above, the nucleophilic addition of phenol to resin 10 (Table 3, entry 3) proceeded at a faster rate in DMSO and DMF compared with THF. However, even in these solvents, the addition reaction required 36 h to bring about high conversion of the phenol adduct. Aryl ether 11c was then obtained in 48% yield (2 steps) and 93% crude purity after cyclitive removal.
In order to explore the question of regioselectivity, the loading reaction was next attempted with 2,4-difluorobenzonitrile. As illustrated in Scheme 4, this reaction could lead either to the desired aryloxime intermediate 12 through displacement of the 2-fluoro group, or to an undesired isomer 13 through displacement of the 4-fluoro group. Treatment of the unsymmetrical nitrile with the potassium salt of resin 1 gave a 85% loading yield based on weight. Although the ratio of 12 to 13 was not determined, the presumed mixture was then hydrolyzed under the standard cyclization conditions to yield a single product 14a (as determined by HPLC and NMR) in 74% isolated yield. The high selectivity observed for the formation of the desired product could arise from either of two pathways. On one hand, the resin loading reaction may be quite selective for the 2-position, giving primarily 12, and then subsequently 14a upon cyclorelease. Alternatively, mixtures of the two isomeric aryloxime adducts could be formed with the hydrolysis of intermediate 12 occurring much more rapidly than 13. In order gain insight into the relative contributions of these two pathways, several experiments were performed. Scheme 5 depicts a solution phase model study for the loading reaction of 2,4- difluorobenzonitrile. In this experiment, the potassium salt of acetone oxime was treated with 2,4-difluorobenzonitrile and showed only a slight preference for the addition to the 2-position (1.4:1). (For related regioselectivity studies on solution phase SNAΓ reactions, see (a) Wells, K.M.; Shi, Y.J.; Lynch, J.E.; Humphrey, G.R.; Volante, R.P.; Reider, P.J.; Tetrahedron Lett, 1996, 37, 6439. (b) Sasajima, K; Ona, K.; Katsube, J. ; Yamamoto, H.; Chem. Pharm. Bull., 1978, 26, 2502.) Obviously such poor selectivity, if produced in the solid phase loading reaction, could not account for the >96% purity of cyclorelease product 14a.
Scheme 5. Solution phase model of the loading reaction of 2,4-difluorobenzonitrile.
Figure imgf000051_0001
1.4 : 1
Scheme 6 illustrates a comparison of the relative rates of hydrolysis for analogous 2- vs 4-substituted aryloximes. Since the isolation of pure 12 and pure 13 was not practical, model resins 3a and 15 were prepared from 2-fluorobenzonitrile and 4-fluorobenzonitrile respectively. As described previously, when resin 3a was treated with the standard cyclitive removal conditions, complete conversion to 3- aminobenzisoxazole was observed after 2h.
Scheme 6. Comparison of the relative rates of oxime hydrolysis for 2- versus 4- substituted aryl oximes.
Figure imgf000052_0001
no reaction
Figure imgf000052_0002
IR analysis of the recovered resin after hydrolysis showed complete disappearance of the nitrile peak, which had clearly been present in the starting material. Alternatively, upon exposure of the isomeric resin 15 to the same hydrolysis conditions, no organic material was released from the solid-phase. In this experiment, IR analysis of the recovered resin confirmed that the nitrile remained intact, apparently unaffected by exposure to the aqueous acid.
These observations led us to reexamine the reaction shown in Scheme 4. This time, resin 12 and 13 were recovered after the cyclorelease reaction was complete, and characterized by IR spectroscopy. The analysis revealed that a nitrile peak was still present on the resin, although the intensity of the nitrile was diminished relative to that observed prior to hydrolysis. These data support the hypothesis that the difference in the hydrolysis rates of intermediate 12 vs 13 serves as the primary source of selectivity in this reaction.
Having successfully achieved the selective functionalization of 2,4- difluorobenzonitrile a variety of additional unsymmetrical polyfluorobenzonitriles were carried through the same sequence. The results are presented in Table 4. In all cases tested, HPLC analyses of the crude reaction mixtures confirmed that the desired product is selectively released from the solid phase.
Table 4. Regioselective synthesis of fluoro-3 -amino-benzisoxazoles. entry electrop ile loading product ieH* (n purity)
CN N
1 64 76 (>96)
CN 4a
N
2 25 74 (>96)
14a
Figure imgf000053_0001
»Isola yitM l«r -iιιo atιθgr«ϊ^«-rtdl34se<ioιι »diιg. Crude puriy bised an HPLC tiufys
Synthesis of resin 10: to p-nitrobenzophenone oxime polystyrene (Kaiser) resin (500 mg, 1.07 mmol/g, 0.54 mmol) in a tared 25 mL Kontes
Microfilter Funnel was added THF (7 mL) and potassium r-butoxide (640 μL, 1 M
in THF, 0.642 mmol). After shaking by hand for several minutes, the resin turned a deep purple color. To this suspension was added 2,6-difluorobenzonitrile (150 mg, 1.07 mmol). The reaction vessel was rotated at 55 °C in a Robbins oven for 8 h to give resin 10 followed by cooling for 1 h. The resin was then rinsed with 2 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 x 5 mL of H20, and 4 5 mL of MeOH.
The resin was dried in a 35 °C vacuum oven for 12 h to give a Δwt = 40.1 mg
(63% loading yield).
Synthesis of 4-[2-(p-chlorophenyl)ethoxy]-3-amino-1 ,2-benzisoxazole
(11a): In a separate vial, 2-(p-chlorophenyl)ethanol (128 μL, 1.07 mmol) was
dissolved in 1 mL of THF followed by the addition of potassium f-butoxide (1.07 mL, 1 M in THF, 1.07 mmol). This alkoxide solution was then added to a THF suspension (6 mL) of resin 10 (540.1 mg, assume 0.535 mmol). The reaction vessel was rotated for 12 h in a 55 °C oven. The resin was then rinsed 2 5 mL of CH2CI2, 2 5 mL of MeOH, 2 x 5 mL of H2O, and 4 x 5 mL of MeOH. The resin was dried in a 35 °C vacuum oven for 3 h. TFA (4 mL) and 5 N HCIaq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven. The TFA/HCIaq was collected and the resin was rinsed with 2 5 mL of CH2CI2. These washings were combined and concentrated in vacuo to give the crude product 11a (>96% purity by reverse phase HPLC) which was purified by radial chromatography on a 2 mm plate eluting with 50% EtOAc/Hexanes. Concentration of the product containing fractions gave pure 6-[(p- chlorophenyl)oxymethyl]-3-amino-1 ,2-benzisoxazole (11a) (66 mg, 2 step yield = 68% based on loading yield): HPLC retention time (eluent gradient 10%A to
80%A over 45 min) = 31.8 min. 1H NMR (400 MHz, DMSO-d6) δ 7.39 - 7.31 (m,
5H), 6.93 (d, J = 8.4 Hz, 2H), 6.69 (d, J = 8.4, 1 H), 5.72 (bs, 2H), 4.30 (t, J = 6.4 Hz, 2H), 3.12 (t, J = 6.4 Hz, 2H). MS (ESI) m/z 289 [35CI, (M+H)+], 291 [37CI, (M+H)+]. Anal Calc'd for C15H13CIN2θ2: C, 62.41 ; H, 4.54; N, 9.70; CI, 12.28. Found: C, 62.08; H, 4.61; N, 9.53; CI, 12.41.
Synthesis of 4-pyrrolidino-3-amino-1 ,2-benzisoxazole (11b): to a DMSO suspension (7 mL) of resin 10 (540.1 mg, assume 0.535 mmol) was
added pyrrolidine (134 μL, 1.61 mmol). The reaction vessel was rotated for 8 h
in a 55 °C oven. The resin was then rinsed 2 x 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 x 5 mL of H20, and 4 x 5 mL of MeOH. The resin was dried in a 35 °C vacuum oven for 3 h. TFA (4 mL) and 5 N HCIaq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven. The TFA/HCIaq was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. These washings were combined and concentrated in vacuo to give the crude product 11b (94% purity by reverse phase HPLC) which was purified by radial chromatography on a 2 mm plate eluting with 50% EtOAc/Hexanes. Concentration of the product containing fractions gave pure 4-pyrrolidino-3-amino-1 ,2-benzisoxazole (11b) (54 mg, 2 step yield = 80% based on loading yield): HPLC retention time (eluent
gradient 5%A to 40%A over 45 min) = 27.9 min. 1H NMR (400 MHz, DMSO-d6) δ 7.27 (t, J = 8.0 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.55 (d, J = 7.6, 1H), 5.62 (bs, 2H), 3.27- 3.20 (m, 4H), 1.92 - 1.83 (m, 4H). MS (ESI) m/z 204 (M+H)+. Anal Calc'd for CnH13N3O: C, 65.01; H, 6.45; N, 20.67. Found: C, 64.46 H, 6.22; N, 20.11.
Synthesis of 4-phenoxy-3-amino-1 ,2-benzisoxazole (11c): to a DMF suspension (7 mL) of resin 10 (540.1 mg, assume 0.535 mmol) was added phenol (503 mg, 5.35 mmol) and K2C03 (738 mg, 5.35 mmol). The reaction vessel was rotated for 36 h in a 55 °C oven. The resin was then rinsed 2 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 x 5 mL of H2O, and 4 5 mL of MeOH. The resin was dried in a 35 °C vacuum oven for 3 h. TFA (4 mL) and 5 N HCIaq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven. The TFA/HCIaq was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. These washings were combined and concentrated in vacuo to give the crude product 11c (93% purity by reverse phase HPLC) which was purified by radial chromatography on a 2 mm plate eluting with 50% EtOAc/Hexanes. Concentration of the product containing fractions gave pure 4-phenoxy-3-amino- 1 ,2-benzisoxazole (11c) (38 mg, 2 step yield = 48% based on loading yield): HPLC retention time (eluent gradient 10%A to 90%A over 45 min) = 23.7 min. 1H
NMR (400 MHz, DMSO-d6) δ 7.44 (t, J = 7.6 Hz, 2H), 7.36 (t, J = 9.6 Hz, 1 H),
7.26 - 7.15 (m, 3H), 7.10 (d, J = 8.4 Hz, 1 H), 6.36 (d, J = 7.6 Hz, 1 H), 6.02 (bs, 2H). MS (ESI) m/z 227 (M+H)+. Anal Calc'd for C13H10N2O2: C, 69.02; H, 4.46; N, 12.38. Found: C, 69.21 H, 4.06; N, 12.75.
General procedure for the synthesis of fluoro-3-amino-1,2- benzisoxazoles 14a - f: to p-nitrobenzophenone oxime polystyrene (Kaiser) resin (500 mg, 1.07 mmol/g, 0.54 mmol) in a tared 25 mL Kontes Microfilter
Funnel was added THF (7 mL) and potassium f-butoxide (640 μL, 1 M in THF,
0.642 mmol). After shaking by hand for several minutes, the resin turned a deep purple color. To this suspension was added 2,4-difluorobenzonitrile (150 mg, 1.07 mmol). The reaction vessel was rotated at 55 °C in a Robbins oven for 12 h followed by cooling for 1 h. The resin was then rinsed with 2 x 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 5 mL of H20, and 4 x 5 mL of MeOH. The resin was dried
in a 35 °C vacuum oven for 12 h to give a Δwt = 52.4 mg (90% loading yield). An
IR analysis of the resin shows a nitrile stretching peak at 2230.3 cm"1. TFA (4 mL) and 5 N HCIaq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven. The TFA/HCIaq was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. An IR analysis of the resin after the cyclorelease reaction shows a diminished nitrile stretching peak. The CH2CI2 washings were combined and concentrated in vacuo to give the crude product 14a (>96% purity by reverse phase HPLC) that was purified by radial chromatography on a 2 mm plate eluting with 50% EtOAc/Hexanes. Concentration of the product containing fractions gave pure 6-fluoro-3-aminobenzisoxazole (14a): (40mg, 2 step yield = 74% based on loading yield): HPLC retention time (eluent gradient 10%A to
60%A over 45 min) = 13.3 min. 1H NMR (400 MHz, DMSO-d6) δ 7.81 (dd, J -
8.8, 5.2 Hz, 1 H), 7.36 (dd, J = 9.6, 2.0 Hz, 1 H), 7.11 (ddd, J = 11.2, 8.8, 2.4 1H), 6.44 (bs, 2H). MS (FD) m/z 152 M+. Anal Calc'd for C7H5FN2O: C, 55.27; H, 3.31 ; N, 18.41. Found: C, 55.21 H, 3.27; N, 18.20.
7-fluoro-3-aminobenzisoxazole (14b): (30mg, 2 step yield = 56% based on loading yield): >96% crude purity. HPLC retention time (eluent gradient 5%A
to 40%A over 45 min) = 20.1 min. 1H NMR (400 MHz, DMSO-d6) δ 7.63 (dd, J =
8.4, 1.2 Hz, 1 H), 7.40 (ddd, J = 11.6, 8.4, 0.8 Hz, 1 H), 7.21 (td, J = 8.0, 4.4 1 H), 6.58 (bs, 2H). MS (FD) m/z 152 M+. Anal Calc'd for C7H5FN20: C, 55.27; H, 3.31; N, 18.41. Found: C, 55.19 H, 3.45; N, 18.36.
6,7-difluoro-3-aminobenzisόxazole (14e): (23mg, 2 step yield = 27% based on loading yield): 78% crude purity. HPLC retention time (eluent gradient 5%A to 40%A over 45 min) = 27.6 min. 1H NMR (400 MHz, DMSO-d6) δ 7.65 - 7.61 (m, 1H), 7.36 - 7.30 (m, 1 H), 6.62 (bs, 2H). MS (FD) m/z 171 M+. HRMS Calcd for C7H4F2N2O 171.0370, found 171.0368.
4,6-difluoro-3-aminobenzisoxazole (14f): (22mg, 2 step yield = 31% based on loading yield): >96% crude purity. HPLC retention time (eluent gradient
5%A to 40%A over 45 min) = 21.1 min. 1H NMR (400 MHz, DMSO-d6) δ 7.31 (dd,
J = 8.8, 1.2 Hz, 1 H), 7.10 (td, J = 10.0, 2.0 Hz, 1H), 6.34 (bs, 2H). MS (FD) m/z 171 M+. Anal Calc'd for C7H4F2N20: C, 49.42; H, 2.37; N, 16.47. Found: C, 49.36 H, 2.38; N, 16.39.
General Example 10
Carbon-carbon bond forming reactions. Compatibility with versatile methods for forming carbon-carbon bonds on-resin is an important measure of the suitability of any new linker. (Hanessian, S.; Xie, F.; Tetrahedron Lett., 1998, 39, 737.) Our initial efforts focused on the application of catalytic palladium coupling chemistry such as the Suzuki and Sonogashira reactions. Thus, the arylbromide resin 3b was prepared (Lepore, S.D.; Wiley, M.R. J. Org. Chem. 1999, 64, 4547.) and reacted with phenylboronic acid under a variety of palladium catalyzed coupling conditions, then hydrolyzed to give the biaryl product 16a (Table 5). Initially, two sets of conditions that have previously been reported for on-resin Suzuki reactions were evaluated. Use of Pd(PPh3) with triethylamine/DMF for 12 h (Han, Y.; Walker S.D.; Young, R.N.; Tetrahedron Lett., 1996, 37, 2703. Ruhland, B.; Bombrun, A.; Gallop, MA; J. Org. Chem., 1997, 62, 7820.) produced 16a, but led to the formation of numerous biproducts. Alternatively, the use of Pd(PPh3)4, with Na2CO3 in 1 :1 DME/H2O at reflux for 12 h (Frenette, R.; Friesen, R.W.; Tetrahedron Lett., 1994, 35, 9177.), produced 16a in 25 % isolated yield, contaminated only by the cyclization product of the unreacted arylbromide. Due to the superior purity observed with aqueous carbonate, optimization efforts focused on these conditions. Numerous reaction parameters were carefully varied including cosolvent (DMF, DMSO, and THF) and the stoichiometry of the catalyst, boronic acid and sodium carbonate. Although the crude purities were similar for the various solvents which were evaluated, in general THF (Backes, B.J.; Ellman, J.A.; J. Am. Chem. Soc, 1994, 116, 11171) was found to give the highest rate of product formation, and therefore the highest isolated yields. Optimal results were obtained with 1.3 equivalents of 2N Na2CO3, at 55 °C, over 36h. The reaction was rather sensitive to deviation from these conditions, particularly with respect to the amount of added 2N Na2CO3. In control experiments, resin 3b was treated with varying amounts of 2N Na2CO3 in THF at 55 °C over 36h, and no removal of organic material from the resin was observed. As Table 5 shows, the application of the optimized Suzuki conditions to several other substrates (Table 5, entries 2 - 4) provided similar yields and purities.
Table 5. On-resin Suzuki reaction.
Figure imgf000061_0001
boronic . ^ yield'' entr acid product method" . / purity
Figure imgf000061_0002
•Conditions A - D all use 4.0 eq of boronic acid and 5% Pd(PPh3)4, and 36 h. A = 2.5 eq 2 M Na^O-,, DME, reflux; B = 1.0 eq 2 M Na2C03, THF, 55 °C; C = 1.3 eq 2 M Na2C03, THE, 55 °C; D = 1.5 eq 2 M Na2C03, THF, 55 °C isolated yield after chromatography and based on loading. Crude purity based on HPLC analysis. Major impurity in all cases is 6-bromo-3-aminobenzisoxazole. General procedure for the Suzuki coupling reactions with resin 3b: to p-nitrobenzophenone oxime polystyrene (Kaiser) resin (500 mg, 1.07 mmol/g, 0.54 mmol) in a tared 25 mL Kontes Microfilter Funnel was added THF (7 mL)
and potassium f-butoxide (640 μL, 1 M in THF, 0.642 mmol). After shaking by
hand for several minutes, the resin turned a deep purple color. To this suspension was added 4-bromo-2-fluorobenzonitrile (214 mg, 1.07 mmol). The reaction vessel was rotated at 55 °C in a Robbins oven for 12 h to give resin 3b followed by cooling for 1 h. The resin was then rinsed with 2 * 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 5 mL of H2O, and 4 * 5 mL of MeOH. The resin was dried
in a 35 °C vacuum oven for 12 h to give a Δwt = 64 mg (66% loading yield). The
resin was then suspended in THF and to this was added phenylboronic acid (261
mg, 2.14 mmol), Na2CO3 (348 μL, 2 M in H2O, 2.14 mmol), and Pd(PPh3)4. The
vessel was then rotated for 36 h in a 55 °C oven followed by rinsing with 2 x 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 x 5 mL of H2O, and 4 x 5 mL of MeOH. The resin was dried in a 35 °C vacuum oven for 3 h. TFA (4 mL) and 5 N HCIaq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven. The TFA/HCIaq was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. These washings were combined and concentrated in vacuo to give the crude product 16a (91% purity by reverse phase HPLC) which was purified by radial chromatography on a 2 mm plate eluting with 50% EtOAc/Hexanes.
Concentration of the product containing fractions gave pure 6-phenyl-3-amino- 1,2-benzisoxazole (16a): (46 mg, 2 step yield = 58% based on loading yield): HPLC retention time (eluent gradient 10%A to 60%A over 45 min) = 13.3 min. 1H
NMR (400 MHz, DMSO-d6) δ 7.86 (d, J = 8.4 Hz, 1 H), 7.74 - 7.70 (m, 2H), 7.68
(s, 1 H), 7.53 (d, J = 8.0 Hz, 2H), 7.48 - 7.43 (m, 2H), 7.40 - 7.35 (m, 1 H), 6.42 (bs, 2H). MS (ESI) m/z 211 (M+H)+. Anal Calc'd for C130N2O: C, 74.27; H, 4.79; N, 13.32. Found: C, 72.59 H, 4.86; N, 13.36.
6-(3,5-dichlorophenyl)-3-amino-1 ,2-benzisoxazole (16b): 2 step yield = 51 % (based on loading yield). 95% crude purity. HPLC retention time (eluent gradient 20%A to 80%A over 45 min) = 30.4 min. 1 H NMR (400 MHz, DMSO-d6) δ 7.87 (d, J = 8.8 Hz, 1 H), 7.82 (s, 1 H), 7.81 (d, J = 1.6 Hz, 2H), 7.62 - 7.58 (m,
2H), 6.46 (bs, 2H). MS (FD) m/z 278 [35CI+35CI, M+], 280 [35CI+37CI, (M+H)+]. Anal Calc'd for C13H8CI2N20: C, 55.94; H, 2.89; N, 10.04. Found: C, 55.93 H,
2.60; N, 9.85.
6-(3,5-ditrifluoromethylphenyl)-3-amino-1,2-benzisoxazole (16c): 2 step yield = 45% (based on loading yield). 81% crude purity. HPLC retention time (eluent gradient 20%A to 80%A over 45 min) = 31.0 min. 1H NMR (400
MHz, DMSO-de) δ 8.40 (s, 2H), 8.11 (s, 1H), 7.98 (s, 2H), 7.93 (d, J = 8.4 Hz,
1H), 7.76 - 7.71 (m, 2H), 6.49 (bs, 2H). MS (ESI) m/z 347 (M+H)+. Anal Calc'd for Cι5H8F6N2O: C, 52.04; H, 2.33; N, 8.09. Found: C, 52.00 H, 2.06; N, 7.99. 6-(4-formylphenyl)-3«amino-1,2-benzisoxazole (16d): 2 step yield = 43% (based on loading yield). 92% crude purity. HPLC retention time (eluent
gradient 5%A to 40%A over 45 min) = 37.6 min. 1H NMR (400 MHz, DMSO-d6) δ 10.05 (s, 1H), 7.98 (s, 4H), 7.90 (d, J = 8.4 Hz, 1 H), 7.82 (s, 1H), 7.63 (dd, J = 8.4, 1.6 Hz, 1 H), 6.46 (bs, 2H). MS (ESI) m/z 239 (M+H)+. HRMS Calcd for C14H10N2O2 (M+H)+ 239.0821 , found 239.1816.
General Example 11 Application of the Sonogashira reaction to resin 3b proved less difficult than the Suzuki coupling. We were able to couple phenethylacetylene to 3b to give alkyne 17 in a
58% 2-step yield using Pd(PPh3) /Cul in THF (Scheme 8) (Kahn, S.I.;
Grinstaff, M.W.; Tetrahedron lett.; 1998, 39, 8031.) Again, as in the Suzuki chemistry, significantly better results were obtained with THF as the reaction solvent. The Pd2(dba);$/CuI/Et3N conditions described by Moore (Nelson, J.C.;
Young, J.K.; Moore, J.S.; J. Org. Chem., 1996, 61, 8160.) failed to give
reasonable yields and purities.
Scheme 8. On-resin Sonogashira coupling.
Figure imgf000065_0001
Figure imgf000065_0002
°> isolated yield = 58% crude purity = 93%
Sonogashira coupling with resin 3b: resin 3b was prepared in 66% loading yield from 0.535 mmol of Kaiser oxime 1 as detailed above. The resin was then suspended in THF and to this was added 4-phenylbutyne (280 mg,
2.14 mmol), Et3N (500 μL), Cul (5.1 mg, 0.027 mmol), and Pd(PPh3)4 (31 mg,
0.027 mmol). The vessel was then rotated for 36 h in a 55 °C oven followed by rinsing with 2 x 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 5 mL of H20, and 4 x 5 mL of MeOH. The resin was dried in a 35 °C vacuum oven for 3 h. TFA (4 mL) and 5 N HCIaq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven. The TFA/HCIaq was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. These washings were combined and concentrated in vacuo to give the crude product 17 (93% purity by reverse phase HPLC) which was purified by radial chromatography on a 2 mm plate eluting with 50% EtOAc/Hexanes. Concentration of the product containing fractions gave pure 6- (4-phenylbutynyl)-3-amino-1 ,2-benzisoxazole (17): (58 mg, 2 step yield = 58%) based on loading yield): HPLC retention time (eluent gradient 20%A to 85%A over 45 min) = 26.2 min. 1H NMR (400 MHz, DMSO-d6) δ 7.73 (d, J - 8.0
Hz, 1 H), 7.38 (s, 1 H), 7.29 - 7.27 (m, 4H), 7.21 - 7.15 (m, 2H), 6.43 (bs, 2H), 2.84 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H). MS (ESI) m/z 263 (M+H)+. HRMS Calcd for C13H10N2O 263.1184, found 263.1172.
General Example 12
The acquisition of aldehyde resin 18 (Scheme 9) from the Suzuki reaction with 3b (Table 5, entry 4) provided an opportunity to evaluate the compatibility of the aryloxime linker with the Horner-Emmons olefination. Thus, treatment of 18 with the anion of trimethylphosphonoacetate in THF (preformed with n-BuLi at 0
°C) gave olefin 19 in 52% isolated yield (3-steps, based on loading of resin 1)
and 92%o purity. (Chin, J.; Fell, B.; Shapiro, M.J.; Tomesch, J.; Wareing, J.R.; Bray, A.M.; J. Org. Chem., 1997, 62, 538. Rotella, D.P.; J. Am. Chem. Soc, 1996, 118, 12246.) The major impurity in this reaction is the cinnamic acid derivative which likely results from competing ester hydrolysis in the cyclitive removal step. Scheme 9. On-resin Horner-Emmons olefination
Figure imgf000067_0001
Horner-Emmons olefination to give 19: to p-nitrobenzophenone oxime polystyrene (Kaiser) resin (500 mg, 1.07 mmol/g, 0.54 mmol) in a tared 25 mL Kontes Microfilter Funnel was added THF (7 mL) and potassium f-butoxide (640
μL, 1 M in THF, 0.642 mmol). After shaking by hand for several minutes, the
resin turned a deep purple color. To this suspension was added 4-bromo-2- fluorobenzonitrile (214 mg, 1.07 mmol). The reaction vessel was rotated at 55 °C in a Robbins oven for 12 h to give resin 3b followed by cooling for 1 h. The resin was then rinsed with 2 5 mL of CH2CI2, 2 5 mL of MeOH, 2 x 5 mL of H2O, and 4 5 mL of MeOH. The resin was dried in a 35 °C vacuum oven for 12 h to
give a Δwt = 64 mg (66% loading yield). The resin was then suspended in THF and to this was added 4-formylphenylboronic acid (482 mg, 3.21 mmol), Na2CO3
(348 μL, 2 M in H2O, 0.696 mmol), and Pd(PPh3)4 (31 mg, 0.027 mmol). The vessel was then rotated for 36 h in a 55 °C oven followed by rinsing with 2 x 5 mL of CH2CI2, 2 x 5 mL of MeCN, 2 x 5 mL of H2O, and 4 x 5 mL of MeCN (care was taken to not rinse the resin with methanol in order to avoid methyl acetal formation). The resin was dried in a 35 °C vacuum oven for 3 h to give aldehyde
resin 18. In a separate vial, trimethylphosponoacetate (172 μL, 1.07 mmol) was
dissolved in THF (4 mL) and cooled to 0 °C. To this vial was added BuLi (602
μL, 0.96 mmol, 1.6 M in hexanes) dropwise. This THF solution was then added
dropwise by syringe to a suspension of resin 18 in THF (4 mL) and the vessel was rotated for 6 h at room temp. This was followed by rinsing with 2 x 5 mL of CH2CI2, 2 x 5 mL of MeOH, 2 x 5 mL of H2O, and 4 x 5 mL of MeOH. The resin was then dried in a 35 °C vacuum oven for 3 h. TFA (4 mL) and 5 N HCIaq (1 mL) were then added to the resin and the vessel was rotated for 2 h in a 55 °C oven. The TFA/HCIaq was collected and the resin was rinsed with 2 x 5 mL of CH2CI2. These washings were combined and concentrated in vacuo to give the crude product 19 (92% purity by reverse phase HPLC) which was purified by radial chromatography on a 2 mm plate eluting with 50% EtOAc/Hexanes. Concentration of the product containing fractions gave pure 6-[4- (methoxycarbonylethylenyl)phenyl]-3-amino-1 ,2-benzisoxazole (19): (47 mg, 3 step yield = 52% based on loading yield of resin 1): HPLC retention time (eluent gradient 20%A to 85%A over 45 min) = 24.3 min. 1H NMR (400 MHz,
DMSO-de) δ 7.86 (d, J = 8.0 Hz, 1 H), 7.80 (s, 4H), 7.76 (s, 1 H), 7.69 (d, J = 16.4 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1 H), 6.69 (d, J = 16.4 Hz, 1H), 6.43 (bs, 2H), 3.71 (s, 3H). HRMS Calcd for Cι7H15N2O3 295.1082, found 295.1088.
It should be understood that a wide range of changes and modifications can be made to the embodiments described above. It is therefore intended that the foregoing description illustrates rather than limits this invention, and that it is the appended claims, including all equivalents, which define this invention.

Claims

What is claimed is:
1. A method of synthesizing a polycyclic heterocycle comprising: (a) reacting a compound of the formula (I):
Figure imgf000070_0001
where each of R1, R2, R3 and R4 is a stable moiety independently selected from the group consisting of halo, haloalkyl, cyano, nitro, Ra-Q-, Ra-Q-alkyl, Ra-Q- alkenyl, Ra-Q-alkynyl, Ra-Q-arylalkyl and Ra-Q-aryl;
Ra is hydrogen, alkyl, aryl or arylalkyl; Q is a single bond, -0-, -NR -, -CO-, -NRb-CO-, -CO-NR -, -CO-0-, -O-
CO-, S(0)i, -S(O)rNRb-, -NR -S(0)j; i is O, 1 or 2; j is 1 or 2;
Rb is hydrogen, alkyl, aryl or arylalkyl, where Ra and Rb may together with the nitrogen to which they are attached form a ring;
R5 is halo, nitro, or haloalkyl;
R6 is cyano or a group of the formula (II):
Figure imgf000071_0001
II
L is O, S or NH; and
R7 is alkyl, aryl, arylalkyl, alkyloxyalkyl, aryloxyalkyl, alkylamino, dialkylamino, arylamino, alkoxycarbonyl, amino, alkoxy, hydroxy or heteroaryl; with a compound of the formula (III):
Figure imgf000071_0002
where g is a solid support; h is alkyl, arylalkyl or aryl; and
R13 is -NH-, -O- or -S-; to form a corresponding intermediate of the formula (IV):
Figure imgf000072_0001
IV
where n is an integer > 0, and g and h are as defined above;
(b) optionally derivatizing one or more of R1, R2, R3 and R4to form a corresponding intermediate of the formula (IV); and
Figure imgf000072_0002
IV where the R1 , R2 , R3 and R4 substituents are each independently the same as substituents R1, R2, R3 and R4 respectively if not derivatized or are each independently the chemically derivatized substituents respectively; and
(c) cyclizing compound IV to form a compound (V), which is displaced from the solid support;
Figure imgf000073_0001
V where R7 is amino, hydroxy or the same as R7.
2. The method of claim 1 , wherein R1, R2, R3 and R4 are hydrogen, g is a polystyrene resin and h is p-nitrophenyl.
3. The method of claim 1 , wherein at least one of R1, R2, R3 and R4 is chemically derivatized.
4. The method of claim 1 , wherein R1 is CF3.
5. The method of claim 1 , wherein R3 is CF3.
6. The method of claim 1 , wherein R4 is CF3.
7. The method of claim 1 , wherein R3 is selected from the group consisting of hydroxy, hydroxyalkyl and alkoxy.
8. The method of claim 1 , wherein R3 is halo.
9. The method of claim 1 , wherein R2 is cyano.
10. The method of claim 1 , wherein R3 is nitro.
11. The method of claim 1 , wherein R3 is -CH2-0-TBS and R3' is a group of the formula (VI):
Figure imgf000074_0001
VI
12. The method of claim 1 , wherein R3 is -CH2-N-BOC and R3' is a group of the formula (VII):
Figure imgf000074_0002
VII
13. The method of claim 1 , wherein R5 is fluoro, chloro or nitro.
14. A compound of the formula (IV):
Figure imgf000075_0001
IV where g is a solid support,
n is an integer > 0,
h is alkyl, arylalkyl or aryl; R13 is -NH-, -O- or -S-; where each of R1, R2, R3 and R4 is a stable moiety independently selected from the group consisting of halo, haloalkyl, cyano, nitro, Ra-Q-, Ra-Q-alkyl, Ra-Q- alkenyl, Ra-Q-alkynyl, Ra-Q-arylalkyl and Ra-Q-aryl; Ra is hydrogen, alkyl, aryl or arylalkyl;
Q is a single bond, -O-, -NRb-, -CO-, -NRb-CO-, -CO-NRb-, -CO-O-, -O- CO-, S(O)i, -S(0)rNRb-, -NRb-S(0)j; i is O, 1 or 2; j is 1 or 2;
Rb is hydrogen, alkyl, aryl or arylalkyl, where Ra and Rb may together with the nitrogen to which they are attached form a ring; R is halo, nitro, or haloalkyl, and
R6 is cyano or a group of the formula (II):
Figure imgf000076_0001
(il) L is -O-, -S- or -NH-; and
R7 is alkyl, aryl, arylalkyl, alkyloxyalkyl, aryloxyalkyl, alkylamino, dialkylamino, arylamino, alkoxycarbonyl, amino, alkoxy, hydroxy or heteroaryl.
15. The compound of claim 14, wherein g is a polystyrene resin and h is a p-nitrophenyl and all, or any one of R1, R2, R3 and R4 is chemically derivatizable.
16. The compound of claim 14, wherein R1, R2, R3 and R4 are hydrogen.
17. The compound of claim 14, wherein R1 is CF3.
18. The compound of claim 14, wherein R3 is CF3.
19. The compound of claim 14, wherein R4 is CF3.
20. The compound of claim 14, wherein R3 is methoxy.
21. The compound of claim 14, wherein R3 is alkyl, dialkylamino, arylalkyl-amino, methylcarbonylalkyj, amino-CO-alkyl or heteroaryl.
22. The compound of claim 14, wherein R3 is halo.
23. The compound of claim 14, wherein R2 is cyano.
24. The compound of claim 14, wherein R2 is nitro.
25. The compound of claim 14, wherein R5 is fluoro, chloro or nitro.
26. A library of polycyclic heterocycle compounds where said library contains a plurality of diverse compounds (V):
Figure imgf000077_0001
V having diversity in at least one of the substituent groups R1 , R2 , R3 , R , R7' and R13; where each of R1, R2, R3 and R4 is a stable moiety independently selected from the group consisting of halo, haloalkyl, cyano, nitro, Ra-Q-, Ra-Q-alkyl, Ra-Q- alkenyl, Ra-Q-alkynyl, Ra-Q-arylalkyl and Ra-Q-aryl;
Ra is hydrogen, alkyl, aryl or arylalkyl;
Q is a single bond, -O-, -NRb-, -CO-, -NRb-CO-, -CO-NRb-, -CO-O-, -O- CO-, S(O)i, -S(0)rNRb-, -NRb-S(O)j; i = 0, 1 or 2; j is 1 , 2; Rb is hydrogen, alkyl, aryl or arylalkyl, where Ra and Rb may together with the nitrogen to which they are attached form a ring;
R5 is halo, nitro, or haloalkyl, and
n is an integer > 0;
R7 is alkyl, aryl, arylalkyl, alkyloxyalkyl, aryloxyalkyl, alkylamino, dialkylaminoarylamino, alkoxycarbonyl, amino, alkoxy, hydroxy or heteroaryl; and
R13 is -NH-, -O- or -S-.
27. A process for preparing a combinatorial library of polycyclic heterocycle compounds of the formula (V):
Figure imgf000078_0001
V having diversity in at least one of the substituent groups R1 , R2 , R3 , R4',
R7 and R13 and where each library compound is made in a reaction zone, said process comprising: (a) reacting a compound of the formula (I):
Figure imgf000079_0001
where each of R1, R2, R3 and R4 is a stable moiety independently selected from the group consisting of halo, haloalkyl, cyano, nitro, Ra-Q-, Ra-Q-alkyl, Ra-Q- alkenyl, Ra-Q-alkynyl, Ra-Q-arylalkyl and Ra-Q-aryl;
Ra is hydrogen, alkyl, aryl or arylalkyl;
Q is a single bond, -O-, -NRb-, -CO-, -NRb-CO-, -CO-NRb-, -CO-O-, -O- CO-, S(O)„ -S(O)rNRb-, -NRb-S(O) ; i is O, 1 or 2; j is 1 or 2;
Rb is hydrogen, alkyl, aryl or arylalkyl, where Ra and R may together with the nitrogen to which they are attached form a ring;
R5 is halo, nitro, or haloalkyl, and
R6 is cyano or a group of the formula (II):
Figure imgf000079_0002
L is -O-, -S- or -NH-;
R7 is alkyl, aryl, arylalkyl, alkyloxyalkyl, aryloxyalkyl, alkylamino, dialkylamino arylamino, alkoxycarbonyl, amino, alkoxy, hydroxy or heteroaryl; with a compound of the formula (III):
H
Figure imgf000080_0001
(III) where g is a solid support; h is alkyl, arylalkyl or aryl; and R13 is -NH-, -O- or -S-; to form a corresponding intermediate of the formula (IV):
Figure imgf000080_0002
IV
where n is an integer > 0, and g and h are as defined above; (b) optionally derivatizing one or more of R1, R2, R3 and R to form a corresponding intermediate of the formula (IV);
Figure imgf000081_0001
IV where the R ' , R^ , Rύ and R" substituents are each independently the same as substituents R1 , R2, R3 and R4 respectively if not derivatized or are each independently the chemically derivatized substituents respectively; and
(c) cyclizing compound (IV) to form a compound of the formula (V), which is displaced from the solid support;
Figure imgf000081_0002
V where R7 is amino, hydroxy or the same as R7.
28. An assay kit for the identification of lead compounds, said kit comprising assay materials and well plate apparatus where each well in said apparatus contains a compound of the library of claim 26.
29. An apparatus suitable as a replacement element in an automated assay machine as a source of individual members of a library of structurally related compounds, said apparatus comprising a 2-dimensional array of defined reservoirs, each reservoir containing a compound of said library, where said structurally related compounds are of the formula (V):
Figure imgf000082_0001
V having diversity in at least one of the substituent groups R1', R2 , R3 , R4', R7' and R13; where each of R1, R2, R3 and R4 is a stable moiety independently selected from the group consisting of halo, haloalkyl, cyano, nitro, Ra-Q-, Ra-Q-alkyl, Ra-Q- alkenyl, Ra-Q-alkynyl, Ra-Q-arylalkyl and Ra-Q-aryl;
Ra is hydrogen, alkyl, aryl or'arylalkyl; Q is a single bond, -O-, -NRb-, -CO-, -NRb-CO-, -CO-NRb-, -CO-O-, -O- CO-, S(0)i, -S(O)rNR -, -NRb-S(O)j; i is O, 1 or 2; j is 1 or 2; Rb is hydrogen, alkyl, aryl or arylalkyl, where Ra and Rb may together with the nitrogen to which they are attached form a ring; and n is an integer > 0;
R7 is alkyl, aryl, arylalkyl, alkyloxyalkyl, aryloxyalkyl, alkylamino, dialkylamino, arylamino, alkoxycarbonyl, amino, alkoxy, hydroxy or heteroaryl; and
R13 is -NH-, -O- or -S-.
PCT/US1999/026803 1998-11-12 1999-11-12 Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles WO2000027627A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU18184/00A AU1818400A (en) 1998-11-12 1999-11-12 Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10820898P 1998-11-12 1998-11-12
US60/108,208 1998-11-12
US14549299P 1999-07-22 1999-07-22
US60/145,492 1999-07-22

Publications (1)

Publication Number Publication Date
WO2000027627A1 true WO2000027627A1 (en) 2000-05-18

Family

ID=26805642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026803 WO2000027627A1 (en) 1998-11-12 1999-11-12 Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles

Country Status (2)

Country Link
AU (1) AU1818400A (en)
WO (1) WO2000027627A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135023A1 (en) * 1998-11-12 2001-09-26 Eli Lilly And Company Aminobenzisoxazole compounds and libraries thereof
US6569879B2 (en) * 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
WO2004113304A1 (en) * 2003-05-22 2004-12-29 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
DE102005038947A1 (en) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituted benzo [d] isoxazol-3-yl-amine compounds and their use in medicaments
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7435731B2 (en) 2004-02-27 2008-10-14 Roche Palo Alto Llc Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same
US7452880B2 (en) 2004-02-27 2008-11-18 Nidhi Arora Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same
US7473701B2 (en) 2002-03-11 2009-01-06 Aventis Pharma S.A. Substituted indazoles, compositions containing them, method of production and use
US7495015B2 (en) 2004-02-27 2009-02-24 Roche Palo Alto Llc Indazole derivatives and methods for using the same
US7563799B2 (en) 2005-08-25 2009-07-21 Roche Palo Alto Llc Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors
JP2010533731A (en) * 2007-07-16 2010-10-28 アボット・ラボラトリーズ Indazoles, benzisoxazoles and benzisothiazoles as protein kinase inhibitors
US8293738B2 (en) 2010-05-12 2012-10-23 Abbott Laboratories Indazole inhibitors of kinase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510240A (en) * 1990-07-02 1996-04-23 The Arizona Board Of Regents Method of screening a peptide library
EP0754672A1 (en) * 1994-04-06 1997-01-22 Shionogi & Co., Ltd. Gamma-substituted phenylacetic acid derivative, process for producing the same, and agricultural bactericide containing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510240A (en) * 1990-07-02 1996-04-23 The Arizona Board Of Regents Method of screening a peptide library
EP0754672A1 (en) * 1994-04-06 1997-01-22 Shionogi & Co., Ltd. Gamma-substituted phenylacetic acid derivative, process for producing the same, and agricultural bactericide containing the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RIVERO R. A., ET AL.: "EQUIPMENT FOR THE HIGH-THROUGHPUT ORGANIC SYNTHESIS OF CHEMICAL LIBRARIES.", PRACTICAL GUIDE TO COMBINATORIAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, 29 May 1998 (1998-05-29), US, pages 281 - 307., XP002923059 *
SHUTSKE ET AL.: "A Novel Synthesis of 3-Amino-1,2-Benzisoxazoles - An Entry Into the Isoxazole (3,4,5-ef)(1,4)Benzoxaepine Ring System", J. HETEROCYCLIC CHEM.,, vol. 26, September 1989 (1989-09-01) - October 1989 (1989-10-01), pages 1293 - 1298, XP002923058 *
SUH ET AL.: "3-Amino-1,2-Benzisoxazoles: A New Family of Potent Inhibitors of LTB4 Binding to the Human Neutrophils", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS., vol. 7, no. 4, 1997, pages 389 - 392, XP004136031 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135023A4 (en) * 1998-11-12 2003-03-05 Lilly Co Eli Aminobenzisoxazole compounds and libraries thereof
EP1135023A1 (en) * 1998-11-12 2001-09-26 Eli Lilly And Company Aminobenzisoxazole compounds and libraries thereof
US6569879B2 (en) * 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
US7473701B2 (en) 2002-03-11 2009-01-06 Aventis Pharma S.A. Substituted indazoles, compositions containing them, method of production and use
US7598283B2 (en) 2003-05-22 2009-10-06 Abbott Laboratories, Inc. Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
JP2011088918A (en) * 2003-05-22 2011-05-06 Abbott Lab Indazole, benzisoxazole, and benzisothiazole kinase inhibitor
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US8940778B2 (en) 2003-05-22 2015-01-27 Abbvie Inc. Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US8642776B2 (en) 2003-05-22 2014-02-04 Abbvie Inc. Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US8299243B2 (en) 2003-05-22 2012-10-30 Abbvie Inc. Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
JP2007500226A (en) * 2003-05-22 2007-01-11 アボット・ラボラトリーズ Indazole, benzisoxazole and benzisothiazole kinase inhibitors
US8063091B2 (en) 2003-05-22 2011-11-22 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2004113304A1 (en) * 2003-05-22 2004-12-29 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
AU2004249675B2 (en) * 2003-05-22 2010-04-15 Abbvie Bahamas Ltd. Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
KR100976076B1 (en) 2003-05-22 2010-08-17 아보트 러보러터리즈 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
JP4810427B2 (en) * 2003-05-22 2011-11-09 アボット・ラボラトリーズ Indazole, benzisoxazole and benzisothiazole kinase inhibitors
EP2246333A1 (en) * 2003-05-22 2010-11-03 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7495015B2 (en) 2004-02-27 2009-02-24 Roche Palo Alto Llc Indazole derivatives and methods for using the same
US7452880B2 (en) 2004-02-27 2008-11-18 Nidhi Arora Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same
US7435731B2 (en) 2004-02-27 2008-10-14 Roche Palo Alto Llc Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same
US7977360B2 (en) 2005-05-18 2011-07-12 Gruenenthal Gmbh Benzo[d]isoxazol-3-yl-amine compounds and their use as vanilloid receptor ligands
DE102005038947A1 (en) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituted benzo [d] isoxazol-3-yl-amine compounds and their use in medicaments
US7563799B2 (en) 2005-08-25 2009-07-21 Roche Palo Alto Llc Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors
JP2010533731A (en) * 2007-07-16 2010-10-28 アボット・ラボラトリーズ Indazoles, benzisoxazoles and benzisothiazoles as protein kinase inhibitors
US8293738B2 (en) 2010-05-12 2012-10-23 Abbott Laboratories Indazole inhibitors of kinase

Also Published As

Publication number Publication date
AU1818400A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
JP5314730B2 (en) Application of bicyclic heterocyclic linking compound having antiviral function and composition containing the compound in the treatment of viral diseases
Kappe The generation of dihydropyrimidine libraries utilizing Biginelli multicomponent chemistry
Olsen et al. A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: effects of fluorine substitution on p K a and binding affinity and evidence for intermolecular C–F⋯ CN interactions
WO2000027627A1 (en) Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
US8153785B2 (en) Stabilizing ligands for regulation of protein function
JP2010501589A (en) Cyclic 11-β hydroxysteroid dehydrogenase type I inhibitor
TW200422298A (en) Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
EP0776327A1 (en) New multimerizing agents
WO2002089782A2 (en) Dioxanes and uses thereof
EP3872081A1 (en) Preparation method for deuterated macrocyclic compound
Scheunemann et al. High regiocontrol in the nucleophilic ring opening of 1-aralkyl-3, 4-epoxypiperidines with amines—a short-step synthesis of 4-fluorobenzyltrozamicol and novel anilidopiperidines
WO2017163257A1 (en) Process for preparing pure lh-pyrazolo[3,4-d] pyrimidine derivative
KR20070107150A (en) Process for preparing protected amidines
Gordeev Combinatorial approaches to harmacophoric heterocycles: A solid‐phase synthesis of 3, 1‐benzoxazine‐4‐ones
Lepore et al. Use of the Kaiser oxime resin in the solid-phase synthesis of 3-aminobenzisoxazoles
Gising et al. A straightforward microwave method for rapid synthesis of N-1, C-6 functionalized 3, 5-dichloro-2 (1 H)-pyrazinones
IL299949A (en) Process for preparing aminofuranes
Lepore et al. Studies on the synthetic compatibility of aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
Liu et al. Solid-phase synthesis of 1, 3, 4-oxadiazoline-5-thione derivatives from resin-bound acylhydrazines
Veeraswamy et al. Synthesis of novel 5-substituted isoxazole-3-carboxamide derivatives and cytotoxicity studies on lung cancer cell line
Pei et al. [1, 2]-Aryl migration in the synthesis of substituted indoles: scope, mechanism, and high throughput experimentation
US6566520B2 (en) Support for synthesis and purification of compounds
Dömling et al. Parallel synthesis of arrays of 1, 4, 5-trisubstituted 1-(4-piperidyl)-imidazoles by IMCR: a novel class of aspartyl protease inhibitors
CN115197261A (en) Synthesis method of oxadiazabenzboron derivative
WO2002051775A2 (en) Methods for forming combinatorial libraries using reductive amination

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 18184

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase